This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid027P
It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid027P.html
Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine.
The full table of all monthly collections is: at house-of-papers.com
PMC searches were done at moremed.org

{{tp|p=33992805|t=2021. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33333292|t=2021. Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33984520|t=2021. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12.|pdf=|usr=}}
{{tp|p=34007862|t=2021. Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34072087|t=2021. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.|pdf=|usr=}}
{{tp|p=34070140|t=2021. Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants.|pdf=|usr=}}
{{tp|p=33916461|t=2021. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M(pro)) Inhibitors.|pdf=|usr=}}
{{tp|p=33947107|t=2021. The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19.|pdf=|usr=}}
{{tp|p=33946802|t=2021. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.|pdf=|usr=}}
{{tp|p=33921378|t=2021. Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19.|pdf=|usr=}}
{{tp|p=33921289|t=2021. Efficacy of Phytochemicals Derived from Avicennia officinalis for the Management of COVID-19: A Combined In Silico and Biochemical Study.|pdf=|usr=}}
{{tp|p=33942600|t=2021. Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.|pdf=|usr=}}
{{tp|p=33947804|t=2021. Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment.|pdf=|usr=}}
{{tp|p=34040779|t=2021. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.|pdf=|usr=}}
{{tp|p=33306283|t=2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.|pdf=|usr=}}
{{tp|p=33356051|t=2021. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.|pdf=|usr=}}
{{tp|p=33332779|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33332778|t=2021. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.|pdf=|usr=}}
{{tp|p=33289973|t=2021. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.|pdf=|usr=}}
{{tp|p=32706531|t=2021. The RECOVERY Platform.|pdf=|usr=}}
{{tp|p=33264557|t=2021. A Large, Simple Trial Leading to Complex Questions.|pdf=|usr=}}
{{tp|p=33264556|t=2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.|pdf=|usr=}}
{{tp|p=33963705|t=2021. [Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].|pdf=|usr=}}
{{tp|p=33846686|t=2021. Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm.|pdf=|usr=}}
{{tp|p=34069866|t=2021. Unveiling the Potential Role of Nanozymes in Combating the COVID-19 Outbreak.|pdf=|usr=}}
{{tp|p=33982600|t=2021. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro.|pdf=|usr=}}
{{tp|p=34045486|t=2021. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34031399|t=2021. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.|pdf=|usr=}}
{{tp|p=33919991|t=2021. L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33924387|t=2021. Impact of COVID-19 Pandemic on Serum Vitamin D Level among Infants and Toddlers: An Interrupted Time Series Analysis and before-and-after Comparison.|pdf=|usr=}}
{{tp|p=33921297|t=2021. Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vitamin D, Vitamin C, Melatonin, and Zinc.|pdf=|usr=}}
{{tp|p=33916257|t=2021. Vitamin C in the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33916087|t=2021. Consequences of the COVID-19 Syndemic for Nutritional Health: A Systematic Review.|pdf=|usr=}}
{{tp|p=33895559|t=2021. Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission.|pdf=|usr=}}
{{tp|p=33321395|t=2021. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status.|pdf=|usr=}}
{{tp|p=34014806|t=2021. The Relationship between COVID-19 Severity and Bacillus Calmette-Guerin (BCG)/ Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study.|pdf=|usr=}}
{{tp|p=33969249|t=2021. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.|pdf=|usr=}}
{{tp|p=34064210|t=2021. Dolosigranulum pigrum Modulates Immunity against SARS-CoV-2 in Respiratory Epithelial Cells.|pdf=|usr=}}
{{tp|p=34069460|t=2021. Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate.|pdf=|usr=}}
{{tp|p=34021797|t=2021. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?|pdf=|usr=}}
{{tp|p=33947420|t=2021. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.|pdf=|usr=}}
{{tp|p=33981493|t=2021. A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19.|pdf=|usr=}}
{{tp|p=33954061|t=2021. Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?|pdf=|usr=}}
{{tp|p=33954055|t=2021. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=34000327|t=2021. Review of antiviral peptides for use against zoonotic and selected non-zoonotic viruses.|pdf=|usr=}}
{{tp|p=34086487|t=2021. Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34073502|t=2021. Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.|pdf=|usr=}}
{{tp|p=34069716|t=2021. Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections.|pdf=|usr=}}
{{tp|p=34064831|t=2021. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.|pdf=|usr=}}
{{tp|p=33801579|t=2021. Comprehensive and Rapid Quality Evaluation Method for the Ayurvedic Medicine Divya-Swasari-Vati Using Two Analytical Techniques: UPLC/QToF MS and HPLC-DAD.|pdf=|usr=}}
{{tp|p=33917573|t=2021. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33917313|t=2021. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.|pdf=|usr=}}
{{tp|p=33921724|t=2021. Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.|pdf=|usr=}}
{{tp|p=33924395|t=2021. Identification of Anti-SARS-CoV-2 Compounds from Food Using QSAR-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Analysis.|pdf=|usr=}}
{{tp|p=34070725|t=2021. A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34073500|t=2021. A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.|pdf=|usr=}}
{{tp|p=34073456|t=2021. Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19.|pdf=|usr=}}
{{tp|p=34071116|t=2021. Lipophilicity, Pharmacokinetic Properties, and Molecular Docking Study on SARS-CoV-2 Target for Betulin Triazole Derivatives with Attached 1,4-Quinone.|pdf=|usr=}}
{{tp|p=33916409|t=2021. Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics.|pdf=|usr=}}
{{tp|p=33918313|t=2021. A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework.|pdf=|usr=}}
{{tp|p=33919660|t=2021. Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics.|pdf=|usr=}}
{{tp|p=33315210|t=2021. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value.|pdf=|usr=}}
{{tp|p=34075294|t=2021. Tocilizumab cost effective in reducing COVID-19-related deaths.|pdf=|usr=}}
{{tp|p=33948076|t=2021. Remdesivir cost effective for severe COVID-19 in China.|pdf=|usr=}}
{{tp|p=34052981|t=2021. The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.|pdf=|usr=}}
{{tp|p=34085181|t=2021. Use of glucocorticoids and azithromycin in the therapy of COVID-19.|pdf=|usr=}}
{{tp|p=33970450|t=2021. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.|pdf=|usr=}}
{{tp|p=33880743|t=2021. Role of pirfenidone in TGF-beta pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.|pdf=|usr=}}
{{tp|p=33359911|t=2021. Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.|pdf=|usr=}}
{{tp|p=34089865|t=2021. Remdesivir in moderate to severe COVID-19: A matter of time?|pdf=|usr=}}
{{tp|p=33369210|t=2021. Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract.|pdf=|usr=}}
{{tp|p=33910199|t=2021. Utilizing Artificial Intelligence to Manage COVID-19 Scientific Evidence Torrent with Risklick AI: A Critical Tool for Pharmacology and Therapy Development.|pdf=|usr=}}
{{tp|p=33892181|t=2021. Antimicrobial photodynamic therapy with hypocrellin B against SARS-CoV-2 infection?|pdf=|usr=}}
{{tp|p=33838311|t=2021. Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.|pdf=|usr=}}
{{tp|p=33836277|t=2021. Photodynamic therapy with curcumin for combating SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33836276|t=2021. Focused role of nanoparticles against COVID-19: Diagnosis and treatment.|pdf=|usr=}}
{{tp|p=33369281|t=2021. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology?|pdf=|usr=}}
{{tp|p=34093097|t=2021. Plant-derived lignans as potential antiviral agents: a systematic review.|pdf=|usr=}}
{{tp|p=34054380|t=2021. Flavonoids are promising safe therapy against COVID-19.|pdf=|usr=}}
{{tp|p=33867898|t=2021. Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.|pdf=|usr=}}
{{tp|p=33376043|t=2021. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.|pdf=|usr=}}
{{tp|p=34033999|t=2021. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.|pdf=|usr=}}
{{tp|p=34029937|t=2021. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.|pdf=|usr=}}
{{tp|p=33961621|t=2021. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.|pdf=|usr=}}
{{tp|p=34061844|t=2021. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study.|pdf=|usr=}}
{{tp|p=34029332|t=2021. COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm.|pdf=|usr=}}
{{tp|p=34061842|t=2021. Ivermectin as a potential treatment for COVID-19?|pdf=|usr=}}
{{tp|p=34106964|t=2021. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.|pdf=|usr=}}
{{tp|p=34106944|t=2021. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.|pdf=|usr=}}
{{tp|p=34081722|t=2021. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry.|pdf=|usr=}}
{{tp|p=34048457|t=2021. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.|pdf=|usr=}}
{{tp|p=34043733|t=2021. Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.|pdf=|usr=}}
{{tp|p=34033648|t=2021. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.|pdf=|usr=}}
{{tp|p=34015003|t=2021. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.|pdf=|usr=}}
{{tp|p=34010326|t=2021. Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation.|pdf=|usr=}}
{{tp|p=34010282|t=2021. Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy.|pdf=|usr=}}
{{tp|p=34003827|t=2021. Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV.|pdf=|usr=}}
{{tp|p=33989354|t=2021. Targeted antiviral treatment using non-ionizing radiation therapy for SARS-CoV-2 and viral pandemics preparedness: Technique, methods and practical notes for clinical application.|pdf=|usr=}}
{{tp|p=33984041|t=2021. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=}}
{{tp|p=33974624|t=2021. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33914780|t=2021. Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.|pdf=|usr=}}
{{tp|p=33886614|t=2021. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.|pdf=|usr=}}
{{tp|p=33882090|t=2021. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33831046|t=2021. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.|pdf=|usr=}}
{{tp|p=34003853|t=2021. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.|pdf=|usr=}}
{{tp|p=33836016|t=2021. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34048156|t=2021. An asymptomatic course of SARS-CoV-2 infection in a patient with 3 different neoplasms and treated with bortezomib: a coincidence or new therapeutic possibility?|pdf=|usr=}}
{{tp|p=34020813|t=2021. Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.|pdf=|usr=}}
{{tp|p=33341305|t=2021. BCG vaccine: Worrying proposal for COVID-19.|pdf=|usr=}}
{{tp|p=34071430|t=2021. Lymphopenia in COVID-19: gammadelta T Cells-Based Therapeutic Opportunities.|pdf=|usr=}}
{{tp|p=34073559|t=2021. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34065294|t=2021. The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.|pdf=|usr=}}

{{tp|p=34086221|t=2021. Rekonvaleszenten-Plasma mildert COVID-19-Verlauf bei Alteren.|pdf=|usr=}}
{{tp|p=34086220|t=2021. Ivermectin gegen Hakenwurm - und Coronavirus?|pdf=|usr=}}
{{tp|p=33904080|t=2021. Budesonid verhindert bei COVID-19 Ubergang zu schwerem Verlauf.|pdf=|usr=}}
{{tp|p=33840851|t=2021. Use of Convalescent Plasma in the Management of COVID-19.|pdf=|usr=}}
{{tp|p=34023987|t=2021. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.|pdf=|usr=}}
{{tp|p=33358936|t=2021. Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.|pdf=|usr=}}
{{tp|p=33961167|t=2021. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=34008129|t=2021. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.|pdf=|usr=}}
{{tp|p=33856591|t=2021. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=33844135|t=2021. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.|pdf=|usr=}}
{{tp|p=33825097|t=2021. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=33837893|t=2021. Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic approaches.|pdf=|usr=}}
{{tp|p=34068970|t=2021. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.|pdf=|usr=}}
{{tp|p=34064568|t=2021. Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability.|pdf=|usr=}}
{{tp|p=34068579|t=2021. In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (M(pro)).|pdf=|usr=}}
{{tp|p=34062737|t=2021. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.|pdf=|usr=}}
{{tp|p=33918595|t=2021. Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor.|pdf=|usr=}}
{{tp|p=33917694|t=2021. Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33976229|t=2021. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation.|pdf=|usr=}}
{{tp|p=33976198|t=2021. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.|pdf=|usr=}}
{{tp|p=34083527|t=2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.|pdf=|usr=}}
{{tp|p=33837182|t=2021. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein.|pdf=|usr=}}
{{tp|p=33863887|t=2021. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.|pdf=|usr=}}
{{tp|p=33859192|t=2021. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.|pdf=|usr=}}
{{tp|p=33273742|t=2021. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.|pdf=|usr=}}
{{tp|p=33977847|t=2021. Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD).|pdf=|usr=}}
{{tp|p=33875867|t=2021. Neutralizing monoclonal antibodies for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33850327|t=2021. Is IL-6 a key cytokine target for therapy in COVID-19?|pdf=|usr=}}
{{tp|p=33961065|t=2021. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.|pdf=|usr=}}
{{tp|p=33948424|t=2021. Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies.|pdf=|usr=}}
{{tp|p=33842188|t=2021. Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies.|pdf=|usr=}}
{{tp|p=34026229|t=2021. Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study.|pdf=|usr=}}
{{tp|p=33976895|t=2021. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33851074|t=2021. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol.|pdf=|usr=}}
{{tp|p=33829849|t=2021. Hypothesis regarding the connections between severe COVID-19 in children and nutrition: a narrative review.|pdf=|usr=}}
{{tp|p=34034769|t=2021. Nutritional screening based on objective indices at admission predicts in-hospital mortality in patients with COVID-19.|pdf=|usr=}}
{{tp|p=34020679|t=2021. The impact of vitamin D supplementation on body fat mass in elite male collegiate athletes.|pdf=|usr=}}
{{tp|p=33838992|t=2021. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.|pdf=|usr=}}
{{tp|p=33308994|t=2021. Determinants of vitamin D activation in patients with acute coronary syndromes and its correlation with inflammatory markers.|pdf=|usr=}}
{{tp|p=33341894|t=2021. Potential benefits of dietary seaweeds as protection against COVID-19.|pdf=|usr=}}
{{tp|p=34064534|t=2021. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.|pdf=|usr=}}
{{tp|p=34072977|t=2021. Relation of Serum Copper Status to Survival in COVID-19.|pdf=|usr=}}
{{tp|p=34064175|t=2021. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.|pdf=|usr=}}
{{tp|p=34064053|t=2021. The Impact of Nutrition on the COVID-19 Pandemic and the Impact of the COVID-19 Pandemic on Nutrition.|pdf=|usr=}}
{{tp|p=34069656|t=2021. Mediterranean Diet and SARS-COV-2 Infection: Is There Any Association? A Proof-of-Concept Study.|pdf=|usr=}}
{{tp|p=34069412|t=2021. COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents.|pdf=|usr=}}
{{tp|p=34068374|t=2021. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.|pdf=|usr=}}
{{tp|p=34068142|t=2021. Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.|pdf=|usr=}}
{{tp|p=34068656|t=2021. Micronutrients Deficiency, Supplementation and Novel Coronavirus Infections-A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33800961|t=2021. In the Age of Viral Pandemic, Can Ingredients Inspired by Human Milk and Infant Nutrition Be Repurposed to Support the Immune System?|pdf=|usr=}}
{{tp|p=33807280|t=2021. Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue.|pdf=|usr=}}
{{tp|p=33801745|t=2021. Vitamin C: From Bench to Bedside.|pdf=|usr=}}
{{tp|p=33947070|t=2021. Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.|pdf=|usr=}}
{{tp|p=33925932|t=2021. Vitamin D Status in Adolescents during COVID-19 Pandemic: A Cross-Sectional Comparative Study.|pdf=|usr=}}
{{tp|p=33925783|t=2021. Nutritional Interventions for COVID-19: A Role for Carnosine?|pdf=|usr=}}
{{tp|p=33880395|t=2021. Ivermectin against COVID-19: The unprecedented consequences in Latin America.|pdf=|usr=}}
{{tp|p=34102081|t=2021. Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19.|pdf=|usr=}}
{{tp|p=33732750|t=2021. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.|pdf=|usr=}}
{{tp|p=34036116|t=2021. Debating the Role of Vitamin D in COVID-19 - An interview with Dr. David Meltzer.|pdf=|usr=}}
{{tp|p=33880393|t=2021. A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.|pdf=|usr=}}
{{tp|p=33879509|t=2021. A nutraceutical strategy for downregulating TGFbeta signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.|pdf=|usr=}}
{{tp|p=33875563|t=2021. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.|pdf=|usr=}}
{{tp|p=33869781|t=2021. COVID-19 severity in relation to sociodemographics and vitamin D use.|pdf=|usr=}}
{{tp|p=33364433|t=2021. Additional baricitinib loading dose improves clinical outcome in COVID-19.|pdf=|usr=}}
{{tp|p=33995792|t=2021. Probiotics potentials in mitigating coronavirus disease (COVID-19) pandemic.|pdf=|usr=}}
{{tp|p=33869886|t=2021. Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.|pdf=|usr=}}
{{tp|p=33842834|t=2021. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.|pdf=|usr=}}
{{tp|p=33859954|t=2021. Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review.|pdf=|usr=}}
{{tp|p=33894123|t=2021. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).|pdf=|usr=}}
{{tp|p=34006644|t=2021. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.|pdf=|usr=}}
{{tp|p=33906951|t=2021. Network medicine framework for identifying drug-repurposing opportunities for COVID-19.|pdf=|usr=}}
{{tp|p=33893175|t=2021. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.|pdf=|usr=}}
{{tp|p=33303654|t=2021. A data-driven approach to identify risk profiles and protective drugs in COVID-19.|pdf=|usr=}}
{{tp|p=34031627|t=2021. Teletherapie - eine innovative Therapiemoglichkeit (auch) fur altere Menschen.|pdf=|usr=}}
{{tp|p=33915202|t=2021. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.|pdf=|usr=}}
{{tp|p=33967350|t=2021. Future antiviral polymers by plasma processing.|pdf=|usr=}}
{{tp|p=33864621|t=2021. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.|pdf=|usr=}}
{{tp|p=33852951|t=2021. An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2.|pdf=|usr=}}
{{tp|p=33840006|t=2021. Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2.|pdf=|usr=}}
{{tp|p=33290940|t=2021. Anti-viral properties of antipsychotic medications in the time of COVID-19.|pdf=|usr=}}
{{tp|p=33357253|t=2021. Evaluation of dietary supplement, functional food and herbal medicine use by dietitians during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33259924|t=2021. Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.|pdf=|usr=}}
{{tp|p=34023513|t=2021. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.|pdf=|usr=}}
{{tp|p=33933611|t=2021. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.|pdf=|usr=}}
{{tp|p=33284977|t=2021. Successful treatment of COVID-19 with colchicine in a kidney transplant recipient.|pdf=|usr=}}
{{tp|p=33972885|t=2021. Effectiveness and feasibility of convalescent blood transfusion to reduce COVID-19 fatality ratio.|pdf=|usr=}}
{{tp|p=33996135|t=2021. Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine.|pdf=|usr=}}
{{tp|p=34089436|t=2021. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy.|pdf=|usr=}}
{{tp|p=33932453|t=2021. Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations.|pdf=|usr=}}
{{tp|p=33360293|t=2021. Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights.|pdf=|usr=}}
{{tp|p=33988482|t=2021. Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?|pdf=|usr=}}
{{tp|p=33992585|t=2021. Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research.|pdf=|usr=}}
{{tp|p=33932822|t=2021. Virucidal and antiviral effects of Thymus vulgaris essential oil on feline coronavirus.|pdf=|usr=}}
{{tp|p=34102594|t=2021. Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure.|pdf=|usr=}}
{{tp|p=34087610|t=2021. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=33832495|t=2021. Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33907666|t=2021. Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus.|pdf=|usr=}}
{{tp|p=33829722|t=2021. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33982984|t=2021. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34095859|t=2021. Protocol for constructing large size human antibody heavy chain variable domain (VH) library and selection of SARS-CoV-2 neutralizing antibody domains.|pdf=|usr=}}
{{tp|p=34078447|t=2021. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33851324|t=2021. Targeting the PANoptosome with miRNA Loaded Mesenchymal Stem Cell Derived Extracellular Vesicles; a New Path to Fight Against the Covid-19?|pdf=|usr=}}
{{tp|p=34035820|t=2021. Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination.|pdf=|usr=}}
{{tp|p=34102020|t=2021. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.|pdf=|usr=}}
{{tp|p=34008922|t=2021. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.|pdf=|usr=}}
{{tp|p=33867777|t=2021. The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33930306|t=2021. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro.|pdf=|usr=}}
{{tp|p=33898692|t=2021. Ivermectin & COVID-19: Let's keep a One Health perspective.|pdf=|usr=}}
{{tp|p=33889481|t=2021. Indoor air quality improvement in COVID-19 pandemic: Review.|pdf=|usr=}}
{{tp|p=34010429|t=2021. Supplementation of the population during the COVID-19 pandemic with vitamins and micronutrients - how much evidence is needed?|pdf=|usr=}}
{{tp|p=33962652|t=2021. Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review.|pdf=|usr=}}
{{tp|p=33813870|t=2021. Translation, Adaptation, and Validation of Chronic Kidney Disease Self-Management and Knowledge Instruments for People at Pre-Dialysis Stage in the Arab World.|pdf=|usr=}}

{{tp|p=34009133|t=2021. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.|pdf=|usr=}}
{{tp|p=33825689|t=2021. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.|pdf=|usr=}}
{{tp|p=34032815|t=2021. Mobile App-Reported Use of Traditional Medicine for Maintenance of Health in India During the COVID-19 Pandemic: Cross-sectional Questionnaire Study.|pdf=|usr=}}
{{tp|p=33997535|t=2021. Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir.|pdf=|usr=}}
{{tp|p=33900614|t=2021. Tocilizumab bor overvagas i tidigt skede av svar covid-19.|pdf=|usr=}}
{{tp|p=34000257|t=2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.|pdf=|usr=}}
{{tp|p=34000255|t=2021. Convalescent plasma in patients hospitalised with COVID-19.|pdf=|usr=}}
{{tp|p=33933206|t=2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.|pdf=|usr=}}
{{tp|p=33933194|t=2021. Tocilizumab in COVID-19: some clarity amid controversy.|pdf=|usr=}}
{{tp|p=33545097|t=2021. Azithromycin, RECOVERY, and the power of large, simple trials.|pdf=|usr=}}
{{tp|p=34106642|t=2021. High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34087822|t=2021. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.|pdf=|usr=}}
{{tp|p=33832097|t=2021. The relationship between nutritional status and the prognosis of COVID-19: A retrospective analysis of 63 patients.|pdf=|usr=}}
{{tp|p=33879697|t=2021. The effect of traditional Chinese medicine treatment for post-viral olfactory dysfunction: A protocol for systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33879694|t=2021. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33996501|t=2021. Design of advanced siRNA therapeutics for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=32482538|t=2021. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19.|pdf=|usr=}}
{{tp|p=33967357|t=2021. Effects of Anacardic Acid Monoene on the Respiratory System of Mice Submitted to Acute Respiratory Distress Syndrome.|pdf=|usr=}}
{{tp|p=33317261|t=2021. COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome.|pdf=|usr=}}
{{tp|p=33902254|t=2021. Plitidepsina, un inhibidor del factor de elongacion celular eEF1a y molnupiravir un analogo del ribonucleosido citidina, dos nuevos compuestos quimicos con intensa actividad frente al SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34007141|t=2021. Prevalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traites par biotherapies ou inhibiteurs des JAK : une etude basee sur la population au cours des deux premiers mois de l'epidemie de COVID-19 en Italie.|pdf=|usr=}}
{{tp|p=33875975|t=2021. Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.|pdf=|usr=}}
{{tp|p=34089357|t=2021. COVID-19 in patients with gout on colchicine.|pdf=|usr=}}
{{tp|p=34028704|t=2021. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.|pdf=|usr=}}
{{tp|p=33895812|t=2021. Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021;60:1585-1587.|pdf=|usr=}}
{{tp|p=33856453|t=2021. Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy.|pdf=|usr=}}
{{tp|p=34092840|t=2021. Chemical constituents from coconut waste and their in silico evaluation as potential antiviral agents against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34046177|t=2021. Vitamin D regulation of the immune system and its implications for COVID-19: A mini review.|pdf=|usr=}}
{{tp|p=33824652|t=2021. Role of almitrine bismesylate in managing refractory hypoxemia in COVID19 acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=33897263|t=2021. Research and effectiveness of anti-viral drugs against COVID-19; global public intervention to prevent coronavirus and to improve human health.|pdf=|usr=}}
{{tp|p=33935562|t=2021. Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies.|pdf=|usr=}}
{{tp|p=33835053|t=2021. Nutrition and the microbiota post-COVID-19.|pdf=|usr=}}
{{tp|p=33850422|t=2021. Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.|pdf=|usr=}}
{{tp|p=34039613|t=2021. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.|pdf=|usr=}}
{{tp|p=33958322|t=2021. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.|pdf=|usr=}}
{{tp|p=33318880|t=2021. Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.|pdf=|usr=}}
{{tp|p=34010139|t=2021. A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33958613|t=2021. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.|pdf=|usr=}}
{{tp|p=33953295|t=2021. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.|pdf=|usr=}}
{{tp|p=33953223|t=2021. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19.|pdf=|usr=}}
{{tp|p=34040117|t=2021. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.|pdf=|usr=}}
{{tp|p=34040048|t=2021. A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization.|pdf=|usr=}}
{{tp|p=34040046|t=2021. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34031435|t=2021. Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34021229|t=2021. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study.|pdf=|usr=}}
{{tp|p=34017029|t=2021. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.|pdf=|usr=}}
{{tp|p=34012108|t=2021. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.|pdf=|usr=}}
{{tp|p=34006961|t=2021. Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.|pdf=|usr=}}
{{tp|p=33986405|t=2021. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.|pdf=|usr=}}
{{tp|p=33986382|t=2021. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.|pdf=|usr=}}
{{tp|p=33986351|t=2021. In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33976287|t=2021. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.|pdf=|usr=}}
{{tp|p=33972631|t=2021. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34099831|t=2021. A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.|pdf=|usr=}}
{{tp|p=34099745|t=2021. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=34088975|t=2021. Regulation of the acetylcholine/alpha7nAChR anti-inflammatory pathway in COVID-19 patients.|pdf=|usr=}}
{{tp|p=34075090|t=2021. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.|pdf=|usr=}}
{{tp|p=33574416|t=2021. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33824382|t=2021. Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.|pdf=|usr=}}
{{tp|p=33931664|t=2021. A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing.|pdf=|usr=}}
{{tp|p=33927258|t=2021. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.|pdf=|usr=}}
{{tp|p=33907251|t=2021. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=33907209|t=2021. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.|pdf=|usr=}}
{{tp|p=33893337|t=2021. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.|pdf=|usr=}}
{{tp|p=33888840|t=2021. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.|pdf=|usr=}}
{{tp|p=33888738|t=2021. Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.|pdf=|usr=}}
{{tp|p=33883570|t=2021. Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells.|pdf=|usr=}}
{{tp|p=33863950|t=2021. Reconcile the debate over protective effects of BCG vaccine against COVID-19.|pdf=|usr=}}
{{tp|p=33850241|t=2021. Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.|pdf=|usr=}}
{{tp|p=33850184|t=2021. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.|pdf=|usr=}}
{{tp|p=34091342|t=2021. Transformation of antiviral ribavirin during ozone/PMS intensified disinfection amid COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=34030377|t=2021. Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk.|pdf=|usr=}}
{{tp|p=33360321|t=2021. A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.|pdf=|usr=}}
{{tp|p=33973446|t=2021. [Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli].|pdf=|usr=}}
{{tp|p=34052830|t=2021. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.|pdf=|usr=}}
{{tp|p=34023849|t=2021. SARS-CoV-2 nanobodies 2.0.|pdf=|usr=}}
{{tp|p=34006835|t=2021. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction.|pdf=|usr=}}
{{tp|p=34001849|t=2021. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.|pdf=|usr=}}
{{tp|p=33994545|t=2021. Protein kinase CK2: a potential therapeutic target for diverse human diseases.|pdf=|usr=}}
{{tp|p=33972500|t=2021. Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses.|pdf=|usr=}}
{{tp|p=34075025|t=2021. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro).|pdf=|usr=}}
{{tp|p=33837193|t=2021. FcgammaRIIb blockage: a promising immunotherapy target for severe COVID-19.|pdf=|usr=}}
{{tp|p=33895786|t=2021. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.|pdf=|usr=}}
{{tp|p=33895782|t=2021. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.|pdf=|usr=}}
{{tp|p=33895772|t=2021. Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization.|pdf=|usr=}}
{{tp|p=34078171|t=2021. Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33874769|t=2021. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.|pdf=|usr=}}
{{tp|p=33898925|t=2021. Repositioned Drugs for COVID-19-the Impact on Multiple Organs.|pdf=|usr=}}
{{tp|p=33875977|t=2021. Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report.|pdf=|usr=}}
{{tp|p=33870092|t=2021. A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?|pdf=|usr=}}
{{tp|p=33989977|t=2021. Tuning the Computational Evaluation of Spectroscopic, ELF, LOL, NCI analysis and Molecular Docking of Novel Anti COVID-19 Molecule 4-Dimethylamino Pyridinium 3, 5-Dichlorosalicylate.|pdf=|usr=}}
{{tp|p=34098482|t=2021. Computational details of molecular structure, spectroscopic properties, topological studies and SARS-Cov-2 enzyme molecular docking simulation of substituted triazolo pyrimidine thione heterocycles.|pdf=|usr=}}
{{tp|p=33333412|t=2021. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.|pdf=|usr=}}
{{tp|p=34093778|t=2021. Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: a contemporary review.|pdf=|usr=}}
{{tp|p=33971318|t=2021. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.|pdf=|usr=}}
{{tp|p=33358868|t=2021. Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury.|pdf=|usr=}}
{{tp|p=33378571|t=2021. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=33316396|t=2021. Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin.|pdf=|usr=}}
{{tp|p=34054222|t=2021. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.|pdf=|usr=}}
{{tp|p=33867130|t=2021. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.|pdf=|usr=}}
{{tp|p=33910614|t=2021. Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.|pdf=|usr=}}
{{tp|p=33874981|t=2021. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.|pdf=|usr=}}
{{tp|p=33845867|t=2021. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=}}
{{tp|p=34015868|t=2021. Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=34078038|t=2021. The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia.|pdf=|usr=}}
{{tp|p=34038993|t=2021. Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?|pdf=|usr=}}
{{tp|p=33853308|t=2021. Agir COVID-19 enfeksiyonunda tosilizumab'in etkinligi: Guncel calismalarin derlemes.|pdf=|usr=}}
{{tp|p=33969238|t=2021. Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis.|pdf=|usr=}}
{{tp|p=34092050|t=2021. History repeats itself: Horse originated Hyperimmune sera production against SARS CoV-2.|pdf=|usr=}}
{{tp|p=33878858|t=2021. Pulse Steroid Treatment for Hospitalized Adults with COVID-19.|pdf=|usr=}}
{{tp|p=33918368|t=2021. Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33918301|t=2021. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.|pdf=|usr=}}

{{tp|p=33318996|t=2021. Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy.|pdf=|usr=}}
{{tp|p=34009353|t=2021. Reassessing the Association of Vitamin D Level With SARS-CoV-2 Seropositivity.|pdf=|usr=}}
{{tp|p=34009346|t=2021. Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.|pdf=|usr=}}
{{tp|p=33885775|t=2021. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33880453|t=2021. Commentary: Therapeutic plasma exchange in COVID-19 pediatric patients: Is there a role?|pdf=|usr=}}
{{tp|p=34100005|t=2021. Combining immunomodulators and antivirals for COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=34100004|t=2021. Combining immunomodulators and antivirals for COVID-19.|pdf=|usr=}}
{{tp|p=34100001|t=2021. Convalescent plasma transfusion for pregnant patients with COVID-19.|pdf=|usr=}}
{{tp|p=33870260|t=2021. Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide.|pdf=|usr=}}
{{tp|p=33842908|t=2021. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34015326|t=2021. Immunotherapy in COVID-19: why, who, and when?|pdf=|usr=}}
{{tp|p=33930329|t=2021. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.|pdf=|usr=}}
{{tp|p=33872590|t=2021. Interleukin-6: obstacles to targeting a complex cytokine in critical illness.|pdf=|usr=}}
{{tp|p=34090608|t=2021. Repurposing drugs for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34000236|t=2021. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.|pdf=|usr=}}
{{tp|p=34000235|t=2021. Cytokine adsorption during ECMO for COVID-19-related ARDS.|pdf=|usr=}}
{{tp|p=33991509|t=2021. Inhaled budesonide for early treatment of COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=33991508|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33991507|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33991506|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33844998|t=2021. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33844996|t=2021. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.|pdf=|usr=}}
{{tp|p=33341157|t=2021. Remdesivir for COVID-19 in Europe: will it provide value for money?|pdf=|usr=}}
{{tp|p=34051878|t=2021. Exploiting an early immunological window of opportunity in COVID-19.|pdf=|usr=}}
{{tp|p=34051877|t=2021. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.|pdf=|usr=}}
{{tp|p=33997800|t=2021. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.|pdf=|usr=}}
{{tp|p=33997799|t=2021. Non-steroidal anti-inflammatory drug use in COVID-19.|pdf=|usr=}}
{{tp|p=33349815|t=2021. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.|pdf=|usr=}}
{{tp|p=34031531|t=2021. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.|pdf=|usr=}}
{{tp|p=33990684|t=2021. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.|pdf=|usr=}}
{{tp|p=34002026|t=2021. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).|pdf=|usr=}}
{{tp|p=34063766|t=2021. Strategies for the Production of Soluble Interferon-Alpha Consensus and Potential Application in Arboviruses and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33919577|t=2021. The Three Pillars of COVID-19 Convalescent Plasma Therapy.|pdf=|usr=}}
{{tp|p=33358906|t=2021. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.|pdf=|usr=}}
{{tp|p=33925791|t=2021. Micronutrients in Sepsis and COVID-19: A Narrative Review on What We Have Learned and What We Want to Know in Future Trials.|pdf=|usr=}}
{{tp|p=33950993|t=2021. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.|pdf=|usr=}}
{{tp|p=33950951|t=2021. A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.|pdf=|usr=}}
{{tp|p=34032734|t=2021. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=34032722|t=2021. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.|pdf=|usr=}}
{{tp|p=34011029|t=2021. Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=34011026|t=2021. Efficacy and safety of Xuanfei Baidu granules for treating COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34011025|t=2021. Efficacy of traditional herbal medicine for psychological sequelae in COVID-19 survivors: A protocol for systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34106658|t=2021. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.|pdf=|usr=}}
{{tp|p=34056571|t=2021. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.|pdf=|usr=}}
{{tp|p=33301775|t=2021. Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence.|pdf=|usr=}}
{{tp|p=33920813|t=2021. Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers.|pdf=|usr=}}
{{tp|p=33888152|t=2021. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.|pdf=|usr=}}
{{tp|p=33933603|t=2021. Promising role of defensins peptides as therapeutics to combat against viral infection.|pdf=|usr=}}
{{tp|p=33932547|t=2021. Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro.|pdf=|usr=}}
{{tp|p=34033891|t=2021. Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.|pdf=|usr=}}
{{tp|p=33984466|t=2021. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.|pdf=|usr=}}
{{tp|p=34022374|t=2021. Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection.|pdf=|usr=}}
{{tp|p=33824542|t=2021. Eco-friendly UPLC-MS/MS analysis of possible add-on therapy for COVID-19 in human plasma: Insights of greenness assessment.|pdf=|usr=}}
{{tp|p=33916747|t=2021. A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33925715|t=2021. Next-Generation Probiotics and Their Metabolites in COVID-19.|pdf=|usr=}}
{{tp|p=33921971|t=2021. Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase.|pdf=|usr=}}
{{tp|p=33920489|t=2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.|pdf=|usr=}}
{{tp|p=33331748|t=2021. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: the role of oXiris(R) membrane.|pdf=|usr=}}
{{tp|p=33823571|t=2021. Concomitant use of surfactant and extra-corporeal membrane oxygenation for COVID-19 in an 8-year-old boy.|pdf=|usr=}}
{{tp|p=33856141|t=2021. A TGF - beta2 enriched formula as an oral nutritional supplement for hospitalized COVID-19 patients.|pdf=|usr=}}
{{tp|p=34060731|t=2021. Preventive effects of Pycnogenol(R) on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33995692|t=2021. Eau tonique et quinine - un cocktail de bicentenaire servi en pleine effervescence.|pdf=|usr=}}
{{tp|p=34019535|t=2021. METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2.|pdf=|usr=}}
{{tp|p=33870077|t=2021. Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter.|pdf=|usr=}}
{{tp|p=33995989|t=2021. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.|pdf=|usr=}}
{{tp|p=33854571|t=2021. Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.|pdf=|usr=}}
{{tp|p=33953559|t=2021. Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review.|pdf=|usr=}}
{{tp|p=33995653|t=2021. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).|pdf=|usr=}}
{{tp|p=33886017|t=2021. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.|pdf=|usr=}}
{{tp|p=34058295|t=2021. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG.|pdf=|usr=}}
{{tp|p=34045121|t=2021. Convalescent plasma to treat COVID-19: Following the Argentinian lead.|pdf=|usr=}}
{{tp|p=33994107|t=2021. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.|pdf=|usr=}}
{{tp|p=33994106|t=2021. Efficacy of convalescent plasma therapy in severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=33962885|t=2021. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.|pdf=|usr=}}
{{tp|p=33931359|t=2021. COVID19 immune plasma donation after vaccination: pros and cons.|pdf=|usr=}}
{{tp|p=33896671|t=2021. Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients.|pdf=|usr=}}
{{tp|p=34102319|t=2021. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.|pdf=|usr=}}
{{tp|p=33965621|t=2021. Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.|pdf=|usr=}}
{{tp|p=33931305|t=2021. Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma.|pdf=|usr=}}
{{tp|p=33901641|t=2021. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?|pdf=|usr=}}
{{tp|p=33895379|t=2021. Psychological assessment and lived experiences of recovered COVID-19 patients who presented for convalescent plasma donation.|pdf=|usr=}}
{{tp|p=33839301|t=2021. What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis.|pdf=|usr=}}
{{tp|p=33839300|t=2021. Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.|pdf=|usr=}}
{{tp|p=33887552|t=2021. Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage.|pdf=|usr=}}
{{tp|p=34034765|t=2021. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.|pdf=|usr=}}
{{tp|p=34020680|t=2021. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study.|pdf=|usr=}}
{{tp|p=34019233|t=2021. Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19.|pdf=|usr=}}
{{tp|p=33370597|t=2021. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.|pdf=|usr=}}
{{tp|p=34052578|t=2021. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.|pdf=|usr=}}
{{tp|p=34090962|t=2021. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.|pdf=|usr=}}
{{tp|p=33359190|t=2021. Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint.|pdf=|usr=}}
{{tp|p=33333102|t=2021. A retrospective comparison of drugs against COVID-19.|pdf=|usr=}}
{{tp|p=33845063|t=2021. Quantifying the effect of trypsin and elastase on in vitro SARS-CoV infections.|pdf=|usr=}}
{{tp|p=34099981|t=2021. Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity.|pdf=|usr=}}
{{tp|p=33842675|t=2021. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach.|pdf=|usr=}}
{{tp|p=33842673|t=2021. Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study.|pdf=|usr=}}
{{tp|p=33948452|t=2021. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors.|pdf=|usr=}}
{{tp|p=33869672|t=2021. Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19.|pdf=|usr=}}
{{tp|p=34073401|t=2021. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.|pdf=|usr=}}
{{tp|p=34070524|t=2021. Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34071034|t=2021. GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice.|pdf=|usr=}}
{{tp|p=34067381|t=2021. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned.|pdf=|usr=}}
{{tp|p=34063247|t=2021. Scutellaria barbata D. Don Inhibits the Main Proteases (M(pro) and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.|pdf=|usr=}}
{{tp|p=34069827|t=2021. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.|pdf=|usr=}}
{{tp|p=34069206|t=2021. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34068686|t=2021. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL(pro) In Vitro.|pdf=|usr=}}
{{tp|p=33918958|t=2021. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.|pdf=|usr=}}
{{tp|p=33918914|t=2021. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.|pdf=|usr=}}
{{tp|p=33918670|t=2021. Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33918615|t=2021. The Photosensitizer Octakis(cholinyl)zinc Phthalocyanine with Ability to Bind to a Model Spike Protein Leads to a Loss of SARS-CoV-2 Infectivity In Vitro When Exposed to Far-Red LED.|pdf=|usr=}}
{{tp|p=33916927|t=2021. Neutralizing Antibody Therapeutics for COVID-19.|pdf=|usr=}}
{{tp|p=33946304|t=2021. Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.|pdf=|usr=}}

{{tp|p=33340994|t=2021. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.|pdf=|usr=}}
{{tp|p=33997737|t=2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.|pdf=|usr=}}
{{tp|p=33937736|t=2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply.|pdf=|usr=}}
{{tp|p=33903855|t=2021. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.|pdf=|usr=}}
{{tp|p=33870149|t=2021. RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.|pdf=|usr=}}
{{tp|p=33886937|t=2021. Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.|pdf=|usr=}}
{{tp|p=34085928|t=2021. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.|pdf=|usr=}}
{{tp|p=34057039|t=2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.|pdf=|usr=}}
{{tp|p=33847245|t=2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.|pdf=|usr=}}
{{tp|p=33999367|t=2021. Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel.|pdf=|usr=}}
{{tp|p=33858814|t=2021. Malnutrition and nutrition support in COVID-19: The results of a nutrition support protocol.|pdf=|usr=}}
{{tp|p=34031634|t=2021. Nanozymes to fight the COVID-19 and future pandemics.|pdf=|usr=}}
{{tp|p=33841038|t=2021. An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals.|pdf=|usr=}}
{{tp|p=33934306|t=2021. In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes.|pdf=|usr=}}
{{tp|p=33344687|t=2021. Recent case studies on the use of ozone to combat coronavirus: Problems and perspectives.|pdf=|usr=}}
{{tp|p=33957025|t=2021. Effectiveness of hydrogen peroxide as auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of a randomized double-blind clinical trial.|pdf=|usr=}}
{{tp|p=34021807|t=2021. Mouthrinses against SARS-CoV-2: anti-inflammatory effectivity and a clinical pilot study.|pdf=|usr=}}
{{tp|p=33870079|t=2021. Cytosorb treatment in severe COVID-19 cardiac and pulmonary disease.|pdf=|usr=}}
{{tp|p=33982133|t=2021. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.|pdf=|usr=}}
{{tp|p=33966929|t=2021. Convalescent plasma in the management of COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=34023738|t=2021. A cyclic peptide inhibitor of the SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33894564|t=2021. Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.|pdf=|usr=}}
{{tp|p=34054314|t=2021. Prophylactic effects of probiotics on respiratory viruses including COVID-19: a review.|pdf=|usr=}}
{{tp|p=34068930|t=2021. A Review of the Role of Micronutrients and Bioactive Compounds on Immune System Supporting to Fight against the COVID-19 Disease.|pdf=|usr=}}
{{tp|p=33347987|t=2021. The role of NO in COVID-19 and potential therapeutic strategies.|pdf=|usr=}}
{{tp|p=34017865|t=2021. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.|pdf=|usr=}}
{{tp|p=33969013|t=2021. Iloprost in COVID-19: The Rationale of Therapeutic Benefit.|pdf=|usr=}}
{{tp|p=33928083|t=2021. Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.|pdf=|usr=}}
{{tp|p=33981629|t=2021. Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells.|pdf=|usr=}}
{{tp|p=33968808|t=2021. Could Nutraceutical Approaches Possibly Attenuate the Cytokine Storm in COVID-19 Patients?|pdf=|usr=}}
{{tp|p=34041221|t=2021. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics.|pdf=|usr=}}
{{tp|p=34017819|t=2021. Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor.|pdf=|usr=}}
{{tp|p=33865880|t=2021. Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition.|pdf=|usr=}}
{{tp|p=33316266|t=2021. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors.|pdf=|usr=}}
{{tp|p=33310043|t=2021. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.|pdf=|usr=}}
{{tp|p=33865879|t=2021. Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.|pdf=|usr=}}
{{tp|p=34050796|t=2021. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.|pdf=|usr=}}
{{tp|p=33942765|t=2021. Plasma therapy in COVID-19: All that glitters is not gold.|pdf=|usr=}}
{{tp|p=34024246|t=2021. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.|pdf=|usr=}}
{{tp|p=33958972|t=2021. Ivermectin and COVID-19.|pdf=|usr=}}
{{tp|p=33922914|t=2021. Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study.|pdf=|usr=}}
{{tp|p=33921174|t=2021. Inhibition of SARS-CoV-2 Virus Entry by the Crude Polysaccharides of Seaweeds and Abalone Viscera In Vitro.|pdf=|usr=}}
{{tp|p=34094885|t=2021. Phenolic compounds as promising drug candidates against COVID-19 - An integrated molecular docking and dynamics simulation study.|pdf=|usr=}}
{{tp|p=33308613|t=2021. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?|pdf=|usr=}}
{{tp|p=33958066|t=2021. In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.|pdf=|usr=}}
{{tp|p=33958065|t=2021. Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.|pdf=|usr=}}
{{tp|p=33958057|t=2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33958056|t=2021. A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.|pdf=|usr=}}
{{tp|p=34060334|t=2021. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.|pdf=|usr=}}
{{tp|p=33906927|t=2021. ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia.|pdf=|usr=}}
{{tp|p=33879585|t=2021. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33307107|t=2021. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.|pdf=|usr=}}
{{tp|p=34083071|t=2021. Efecto de la adicion de bemiparina y cefepime al tratamiento habitual en el paciente oncologico con infeccion por SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34059357|t=2021. Prolongacion del intervalo QT en pacientes geriatricos bajo tratamiento por la infeccion por SARS-CoV-2: estudio OCTA-COVID.|pdf=|usr=}}
{{tp|p=33308853|t=2021. Incidencia de la COVID-19 en pacientes en tratamiento cronico con hidroxicloroquina.|pdf=|usr=}}
{{tp|p=33308854|t=2021. Cuestiones por resolver en el tratamiento con glucocorticoides de la infeccion COVID-19.|pdf=|usr=}}
{{tp|p=34056111|t=2021. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.|pdf=|usr=}}
{{tp|p=33846702|t=2021. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.|pdf=|usr=}}
{{tp|p=33878626|t=2021. Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective.|pdf=|usr=}}
{{tp|p=33848919|t=2021. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.|pdf=|usr=}}
{{tp|p=34102600|t=2021. A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine.|pdf=|usr=}}
{{tp|p=34098463|t=2021. Decorin as a possible strategy for the amelioration of COVID-19.|pdf=|usr=}}
{{tp|p=33360447|t=2021. Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues....|pdf=|usr=}}
{{tp|p=33341328|t=2021. Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?|pdf=|usr=}}
{{tp|p=33341032|t=2021. Methylene blue in covid-19.|pdf=|usr=}}
{{tp|p=33333472|t=2021. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?|pdf=|usr=}}
{{tp|p=33308938|t=2021. Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!|pdf=|usr=}}
{{tp|p=33308935|t=2021. Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life(R) (M101).|pdf=|usr=}}
{{tp|p=33867175|t=2021. Terapia combinada de tocilizumab y corticoides en la enfermedad grave por SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33985821|t=2021. Dexametasona en COVID-19: inverted question markun medicamento para todos?|pdf=|usr=}}
{{tp|p=33277927|t=2021. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.|pdf=|usr=}}
{{tp|p=33828895|t=2021. BCG Protection Against COVID-19: Is it Reality or Illusion?|pdf=|usr=}}
{{tp|p=33967626|t=2021. Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection.|pdf=|usr=}}
{{tp|p=33974610|t=2021. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.|pdf=|usr=}}
{{tp|p=33974608|t=2021. An Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts.|pdf=|usr=}}
{{tp|p=33906157|t=2021. Una nueva alternativa: terapia con plasma de convalecientes, posible antidoto en tiempos de COVID-19.|pdf=|usr=}}
{{tp|p=33906156|t=2021. Terapia con plasma de convalecientes en pacientes COVID-19.|pdf=|usr=}}
{{tp|p=34098567|t=2021. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=33978988|t=2021. Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study.|pdf=|usr=}}
{{tp|p=34109257|t=2021. In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34110959|t=2021. Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19.|pdf=|usr=}}
{{tp|p=33835512|t=2021. Use of Remdesivir in Myasthenia gravis and COVID-19.|pdf=|usr=}}
{{tp|p=33860587|t=2021. The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial.|pdf=|usr=}}
{{tp|p=33979464|t=2021. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.|pdf=|usr=}}
{{tp|p=33928690|t=2021. New perspectives on natural flavonoids on COVID-19-induced lung injuries.|pdf=|usr=}}
{{tp|p=34111204|t=2021. Simulated sunlight decreases the viability of SARS-CoV-2 in mucus.|pdf=|usr=}}
{{tp|p=34111191|t=2021. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.|pdf=|usr=}}
{{tp|p=34103373|t=2021. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.|pdf=|usr=}}
{{tp|p=33973262|t=2021. ACE2-based decoy receptors for SARS coronavirus 2.|pdf=|usr=}}
{{tp|p=33893649|t=2021. Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding.|pdf=|usr=}}
{{tp|p=34074129|t=2021. Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce SARS-CoV2-Induced Inflammatory Cytokines Under High Glucose and Uremic Toxin Conditions.|pdf=|usr=}}
{{tp|p=34089033|t=2021. Antibody-laden nasal spray could provide COVID protection - and treatment.|pdf=|usr=}}
{{tp|p=33827113|t=2021. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.|pdf=|usr=}}
{{tp|p=34082438|t=2021. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.|pdf=|usr=}}
{{tp|p=33932964|t=2021. The possibilities of using the effects of ozone therapy in neurology.|pdf=|usr=}}
{{tp|p=33368619|t=2021. Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33858237|t=2021. Coronavirus management and control: Nutrition and alternative medicines.|pdf=|usr=}}
{{tp|p=33847299|t=2021. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.|pdf=|usr=}}
{{tp|p=33902077|t=2021. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.|pdf=|usr=}}
{{tp|p=33967228|t=2021. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.|pdf=|usr=}}
{{tp|p=33316149|t=2021. The influence of the genetic background of the host on vitamin D deficiency in children with COVID-19.|pdf=|usr=}}
{{tp|p=33289321|t=2021. Tracing the path of inhaled nitric oxide: Biological consequences of protein nitrosylation.|pdf=|usr=}}
{{tp|p=33883243|t=2021. Compassionate Use of Remdesivir in Children With Severe COVID-19.|pdf=|usr=}}
{{tp|p=33964992|t=2021. Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.|pdf=|usr=}}
{{tp|p=34009028|t=2021. Photodynamic Therapy and Photobiomodulation on Oral Lesion in Patient with Coronavirus Disease 2019: A Case Report.|pdf=|usr=}}
{{tp|p=33876086|t=2021. A crystallography-based investigation of weak interactions for drug design against COVID-19.|pdf=|usr=}}
{{tp|p=34008647|t=2021. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34110678|t=2021. Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33929758|t=2021. Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral properties.|pdf=|usr=}}
{{tp|p=33882609|t=2021. Die Behandlung eines Patienten mit ausgepragtem Zytokinsturm bei schwerer COVID-19-Pneumonie unter Einsatz von Hamoadsorption in Kombination mit der Gabe von Tocilizumab.|pdf=|usr=}}
{{tp|p=33307968|t=2021. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?|pdf=|usr=}}
{{tp|p=34044609|t=2021. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge.|pdf=|usr=}}

{{tp|p=33888522|t=2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.|pdf=|usr=}}
{{tp|p=34083403|t=2021. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial.|pdf=|usr=}}
{{tp|p=33361100|t=2021. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.|pdf=|usr=}}
{{tp|p=33303541|t=2021. Vitamin D status and seroconversion for COVID-19 in UK healthcare workers.|pdf=|usr=}}
{{tp|p=34002840|t=2021. Intravenous ozonized saline therapy as prophylaxis for healthcare workers (HCWs) in a dedicated COVID-19 hospital in India - A retrospective study.|pdf=|usr=}}
{{tp|p=33829465|t=2021. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.|pdf=|usr=}}
{{tp|p=33829464|t=2021. SARS-CoV-2 infection and H1N1 vaccination: does a relationship between the two factors really exist? A retrospective analysis of a territorial cohort in Ferrara, Italy.|pdf=|usr=}}
{{tp|p=33829431|t=2021. Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.|pdf=|usr=}}
{{tp|p=33829430|t=2021. Ozone therapy may be an option for COVID-19 patients.|pdf=|usr=}}
{{tp|p=33877683|t=2021. Dantrolene repurposed to treat sepsis or septic shock and COVID-19 patients.|pdf=|usr=}}
{{tp|p=33877681|t=2021. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.|pdf=|usr=}}
{{tp|p=34009333|t=2021. Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.|pdf=|usr=}}
{{tp|p=33996744|t=2021. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs.|pdf=|usr=}}
{{tp|p=33889562|t=2021. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33868174|t=2021. New Roles for Vitamin D Superagonists: From COVID to Cancer.|pdf=|usr=}}
{{tp|p=34093569|t=2021. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?|pdf=|usr=}}
{{tp|p=34093548|t=2021. Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.|pdf=|usr=}}
{{tp|p=34054866|t=2021. Intestinal Microbiota-A Promising Target for Antiviral Therapy?|pdf=|usr=}}
{{tp|p=34054808|t=2021. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.|pdf=|usr=}}
{{tp|p=34046038|t=2021. Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure.|pdf=|usr=}}
{{tp|p=34040614|t=2021. Vitamin C May Increase the Recovery Rate of Outpatient Cases of SARS-CoV-2 Infection by 70%: Reanalysis of the COVID A to Z Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=34025650|t=2021. Anti-TNF-alpha agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.|pdf=|usr=}}
{{tp|p=34012456|t=2021. Regulation of Tissue Immune Responses by Local Glucocorticoids at Epithelial Barriers and Their Impact on Interorgan Crosstalk.|pdf=|usr=}}
{{tp|p=34012436|t=2021. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.|pdf=|usr=}}
{{tp|p=33995424|t=2021. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33995420|t=2021. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33995419|t=2021. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.|pdf=|usr=}}
{{tp|p=33995361|t=2021. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.|pdf=|usr=}}
{{tp|p=33968017|t=2021. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.|pdf=|usr=}}
{{tp|p=33897692|t=2021. Case Report: Interferon-gamma Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome.|pdf=|usr=}}
{{tp|p=33868305|t=2021. Commentary: The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33859652|t=2021. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.|pdf=|usr=}}
{{tp|p=33841439|t=2021. Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33833758|t=2021. Bovine Coronavirus Immune Milk Against COVID-19.|pdf=|usr=}}
{{tp|p=33909259|t=2021. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.|pdf=|usr=}}
{{tp|p=33909260|t=2021. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.|pdf=|usr=}}
{{tp|p=34026798|t=2021. Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein: An Integrative in-silico Approach.|pdf=|usr=}}
{{tp|p=34026778|t=2021. Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33968969|t=2021. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.|pdf=|usr=}}
{{tp|p=33968948|t=2021. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.|pdf=|usr=}}
{{tp|p=33937285|t=2021. Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.|pdf=|usr=}}
{{tp|p=33898477|t=2021. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33889590|t=2021. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34054782|t=2021. Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.|pdf=|usr=}}
{{tp|p=33995308|t=2021. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.|pdf=|usr=}}
{{tp|p=33967984|t=2021. Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34079818|t=2021. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.|pdf=|usr=}}
{{tp|p=34055887|t=2021. Current Strategies of Antiviral Drug Discovery for COVID-19.|pdf=|usr=}}
{{tp|p=34046428|t=2021. Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34041263|t=2021. Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34026833|t=2021. A Strategy Based on Loop Analysis to Develop Peptide Epitopes: Application to SARS-CoV-2 Spike Protein.|pdf=|usr=}}
{{tp|p=33937333|t=2021. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.|pdf=|usr=}}
{{tp|p=33912587|t=2021. Inhibition of SARS-CoV-2 3CL M(pro) by Natural and Synthetic Inhibitors: Potential Implication for Vaccine Production Against COVID-19.|pdf=|usr=}}
{{tp|p=33898520|t=2021. Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33869283|t=2021. A Multifunctional Peptide From Bacillus Fermented Soybean for Effective Inhibition of SARS-CoV-2 S1 Receptor Binding Domain and Modulation of Toll Like Receptor 4: A Molecular Docking Study.|pdf=|usr=}}
{{tp|p=34054418|t=2021. Vitamin D, Depressive Symptoms, and Covid-19 Pandemic.|pdf=|usr=}}
{{tp|p=33927594|t=2021. Selective Vagus Nerve Stimulation as a Therapeutic Approach for the Treatment of ARDS: A Rationale for Neuro-Immunomodulation in COVID-19 Disease.|pdf=|usr=}}
{{tp|p=34095193|t=2021. Encapsulated Food Products as a Strategy to Strengthen Immunity Against COVID-19.|pdf=|usr=}}
{{tp|p=33855042|t=2021. Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34093195|t=2021. A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.|pdf=|usr=}}
{{tp|p=34079462|t=2021. Marine Sponge is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold.|pdf=|usr=}}
{{tp|p=34054557|t=2021. Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19.|pdf=|usr=}}
{{tp|p=34054532|t=2021. Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.|pdf=|usr=}}
{{tp|p=34054522|t=2021. Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule and Rational use Against COVID-19 Based on Literature Mining.|pdf=|usr=}}
{{tp|p=34054510|t=2021. beta-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.|pdf=|usr=}}
{{tp|p=34025433|t=2021. Curcumin as a Potential Treatment for COVID-19.|pdf=|usr=}}
{{tp|p=34025406|t=2021. The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application.|pdf=|usr=}}
{{tp|p=34025393|t=2021. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.|pdf=|usr=}}
{{tp|p=34017257|t=2021. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.|pdf=|usr=}}
{{tp|p=34017249|t=2021. The Cholinergic Drug Pyridostigmine Alleviates Inflammation During LPS-Induced Acute Respiratory Distress Syndrome.|pdf=|usr=}}
{{tp|p=34012398|t=2021. Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis.|pdf=|usr=}}
{{tp|p=34012395|t=2021. A Survey Among Italian Physicians During COVID-19 Outbreak. Could Bacillus Calmette-Guerin Vaccine Be Effective Against SARS-CoV2?|pdf=|usr=}}
{{tp|p=34012391|t=2021. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.|pdf=|usr=}}
{{tp|p=34012390|t=2021. Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management.|pdf=|usr=}}
{{tp|p=33995094|t=2021. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections - A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial.|pdf=|usr=}}
{{tp|p=33995078|t=2021. Edible and Herbal Plants for the Prevention and Management of COVID-19.|pdf=|usr=}}
{{tp|p=33995062|t=2021. Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells.|pdf=|usr=}}
{{tp|p=33995053|t=2021. Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation.|pdf=|usr=}}
{{tp|p=33986661|t=2021. Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking.|pdf=|usr=}}
{{tp|p=33981235|t=2021. Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective.|pdf=|usr=}}
{{tp|p=33981229|t=2021. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.|pdf=|usr=}}
{{tp|p=33981214|t=2021. Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.|pdf=|usr=}}
{{tp|p=33967777|t=2021. Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives.|pdf=|usr=}}
{{tp|p=33967773|t=2021. High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.|pdf=|usr=}}
{{tp|p=33967755|t=2021. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.|pdf=|usr=}}
{{tp|p=33959018|t=2021. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.|pdf=|usr=}}
{{tp|p=33953674|t=2021. Giloy Ghanvati (Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish.|pdf=|usr=}}
{{tp|p=33953673|t=2021. Hydroxychloroquine Increased Anxiety-Like Behaviors and Disrupted the Expression of Some Related Genes in the Mouse Brain.|pdf=|usr=}}
{{tp|p=33935717|t=2021. Na(+)/K(+)-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33912048|t=2021. Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019.|pdf=|usr=}}
{{tp|p=33912041|t=2021. Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential.|pdf=|usr=}}
{{tp|p=33912030|t=2021. Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.|pdf=|usr=}}
{{tp|p=33897423|t=2021. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33841165|t=2021. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.|pdf=|usr=}}
{{tp|p=33841143|t=2021. Medicinal Plants in COVID-19: Potential and Limitations.|pdf=|usr=}}
{{tp|p=33833683|t=2021. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.|pdf=|usr=}}
{{tp|p=33828481|t=2021. Fever and Antipyretic Supported by Traditional Chinese Medicine: A Multi-Pathway Regulation.|pdf=|usr=}}
{{tp|p=34093219|t=2021. Can Vitamin D Deficiency Increase the Susceptibility to COVID-19?|pdf=|usr=}}
{{tp|p=34054572|t=2021. The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19.|pdf=|usr=}}
{{tp|p=34077600|t=2021. Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.|pdf=|usr=}}
{{tp|p=33882179|t=2021. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.|pdf=|usr=}}
{{tp|p=33999135|t=2021. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33872387|t=2021. Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34035117|t=2021. Complement control for COVID-19.|pdf=|usr=}}
{{tp|p=33915006|t=2021. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.|pdf=|usr=}}
{{tp|p=34046618|t=2021. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses.|pdf=|usr=}}
{{tp|p=34046603|t=2021. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M(PRO)) through in silico screening supported by molecular docking and a fragment-based pharmacophore model.|pdf=|usr=}}
{{tp|p=33944732|t=2021. Ivermectin for COVID-19: Promising but not yet conclusive.|pdf=|usr=}}
{{tp|p=33944756|t=2021. A qualitative analysis of seven ivermectin formulations in South Africa.|pdf=|usr=}}
{{tp|p=34011224|t=2021. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL(pro) inhibitors: theoretical justification in light of experimental evidences.|pdf=|usr=}}
{{tp|p=34010142|t=2021. Pharmacological activation of STING blocks SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34081820|t=2021. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.|pdf=|usr=}}

{{tp|p=33345848|t=2021. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.|pdf=|usr=}}
{{tp|p=34015316|t=2021. Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment.|pdf=|usr=}}
{{tp|p=34004207|t=2021. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.|pdf=|usr=}}
{{tp|p=34015317|t=2021. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34104202|t=2021. Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms.|pdf=|usr=}}
{{tp|p=34040501|t=2021. Selenium to selenoproteins - role in COVID-19.|pdf=|usr=}}
{{tp|p=33302737|t=2021. Protease-activated receptor 1 as a potential therapeutic target for COVID-19.|pdf=|usr=}}
{{tp|p=33899542|t=2021. Manipulation of genes could inhibit SARS-CoV-2 infection that causes COVID-19 pandemics.|pdf=|usr=}}
{{tp|p=33310152|t=2021. Metformin in acute respiratory distress syndrome: An opinion.|pdf=|usr=}}
{{tp|p=34035463|t=2021. Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion.|pdf=|usr=}}
{{tp|p=33968179|t=2021. Efficiency of antiviral treatment in COVID-19.|pdf=|usr=}}
{{tp|p=33835886|t=2021. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.|pdf=|usr=}}
{{tp|p=33703986|t=2021. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.|pdf=|usr=}}
{{tp|p=33857397|t=2021. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34015985|t=2021. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice.|pdf=|usr=}}
{{tp|p=33844613|t=2021. Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33823733|t=2021. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33962524|t=2021. Antiviral treatment selection for SARS-CoV-2 pneumonia.|pdf=|usr=}}
{{tp|p=34015243|t=2021. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.|pdf=|usr=}}
{{tp|p=34046165|t=2021. Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?|pdf=|usr=}}
{{tp|p=33968364|t=2021. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.|pdf=|usr=}}
{{tp|p=33763201|t=2021. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33879541|t=2021. Rationales and uncertainties for aspirin use in COVID-19: a narrative review.|pdf=|usr=}}
{{tp|p=33894315|t=2021. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening.|pdf=|usr=}}
{{tp|p=33995121|t=2021. Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.|pdf=|usr=}}
{{tp|p=34054909|t=2021. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.|pdf=|usr=}}
{{tp|p=33315181|t=2021. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore.|pdf=|usr=}}
{{tp|p=34061787|t=2021. Vitamin D plasma levels in patients with COVID-19: a case series.|pdf=|usr=}}
{{tp|p=33325523|t=2021. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.|pdf=|usr=}}
{{tp|p=33860869|t=2021. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.|pdf=|usr=}}
{{tp|p=34075339|t=2021. Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus.|pdf=|usr=}}
{{tp|p=34075338|t=2021. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.|pdf=|usr=}}
{{tp|p=34028468|t=2021. The journey of antimalarial drugs against SARS-CoV-2: Review article.|pdf=|usr=}}
{{tp|p=33846694|t=2021. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33363251|t=2021. Computational and network pharmacology analysis of bioflavonoids as possible natural antiviral compounds in COVID-19.|pdf=|usr=}}
{{tp|p=33352565|t=2021. Spices to Control COVID-19 Symptoms: Yes, but Not Only....|pdf=|usr=}}
{{tp|p=33833556|t=2021. Preliminary Exploration of Setting the Disease Severity Score in the Nutritional Risk Screening of Patients with Severe Novel Coronavirus Pneumonia by Applying NRS2002.|pdf=|usr=}}
{{tp|p=33864917|t=2021. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.|pdf=|usr=}}
{{tp|p=33848675|t=2021. A call to caution when hydroxychloroquine is given to elderly patients with COVID-19.|pdf=|usr=}}
{{tp|p=34052406|t=2021. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study.|pdf=|usr=}}
{{tp|p=34048887|t=2021. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.|pdf=|usr=}}
{{tp|p=33930480|t=2021. Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks.|pdf=|usr=}}
{{tp|p=33957219|t=2021. Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study.|pdf=|usr=}}
{{tp|p=33340603|t=2021. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia.|pdf=|usr=}}
{{tp|p=33309910|t=2021. Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease.|pdf=|usr=}}
{{tp|p=33840973|t=2021. Sudarshan Kriya Yoga: A Breath of Hope during COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33960271|t=2021. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33876268|t=2021. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34057560|t=2021. Time for tocilizumab in COVID-19?|pdf=|usr=}}
{{tp|p=34019122|t=2021. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.|pdf=|usr=}}
{{tp|p=33846824|t=2021. Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=34035806|t=2021. Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34037928|t=2021. High-dose steroids for the treatment of severe COVID-19: comment.|pdf=|usr=}}
{{tp|p=33876321|t=2021. High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?|pdf=|usr=}}
{{tp|p=33856664|t=2021. High-dose steroids for the treatment of severe COVID-19.|pdf=|usr=}}
{{tp|p=33837906|t=2021. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.|pdf=|usr=}}
{{tp|p=33355896|t=2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.|pdf=|usr=}}
{{tp|p=33328409|t=2021. Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin.|pdf=|usr=}}
{{tp|p=33847768|t=2021. Antikorpertherapie bei Patienten mit COVID-19.|pdf=|usr=}}
{{tp|p=33902268|t=2021. Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19.|pdf=|usr=}}
{{tp|p=34083855|t=2021. Hypothetical Protective Effects of Crocin Carotenoid against Coronavirus-Induced Organ Damage: The Possible Role of the NF-kappaB Signaling Pathway.|pdf=|usr=}}
{{tp|p=34083848|t=2021. A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33937725|t=2021. Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.|pdf=|usr=}}
{{tp|p=33913665|t=2021. Ultraviolet radiation, vitamin D, and COVID-19.|pdf=|usr=}}
{{tp|p=33860009|t=2021. Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an in silico approach of targeted drug designing.|pdf=|usr=}}
{{tp|p=34015930|t=2021. Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.|pdf=|usr=}}
{{tp|p=33358557|t=2021. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33852936|t=2021. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia.|pdf=|usr=}}
{{tp|p=34018723|t=2021. NMR Based SARS-CoV-2 Antibody Screening.|pdf=|usr=}}
{{tp|p=33832492|t=2021. The use of medicinal plants to prevent COVID-19 in Nepal.|pdf=|usr=}}
{{tp|p=33902620|t=2021. Contested or complementary healing paradigms? Women's narratives of COVID-19 remedies in Mwanza, Tanzania.|pdf=|usr=}}
{{tp|p=34102269|t=2021. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.|pdf=|usr=}}
{{tp|p=34029640|t=2021. Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases.|pdf=|usr=}}
{{tp|p=33831468|t=2021. In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=34057365|t=2021. Add-on Ayurveda Treatment for Early Stage COVID-19: A Single Center Retrospective Cohort Study From Gujarat, India.|pdf=|usr=}}
{{tp|p=33871567|t=2021. SARS-CoV-2 spike therapeutic antibodies in the age of variants.|pdf=|usr=}}
{{tp|p=34041139|t=2021. Hydroxychloroquine: A review of its safety and efficacy in COVID-19.|pdf=|usr=}}
{{tp|p=33838985|t=2021. Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.|pdf=|usr=}}
{{tp|p=34074579|t=2021. Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis.|pdf=|usr=}}
{{tp|p=33897833|t=2021. Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation.|pdf=|usr=}}
{{tp|p=34055047|t=2021. Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19.|pdf=|usr=}}
{{tp|p=33987794|t=2021. The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33904037|t=2021. Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=34052520|t=2021. Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.|pdf=|usr=}}
{{tp|p=33359936|t=2021. Treatment of a case of COVID-19 by intravenous immunoglobulin.|pdf=|usr=}}
{{tp|p=33307274|t=2021. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.|pdf=|usr=}}
{{tp|p=34055580|t=2021. Comparative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients.|pdf=|usr=}}
{{tp|p=33865974|t=2021. Oral antiseptics against coronavirus: in-vitro and clinical evidence.|pdf=|usr=}}
{{tp|p=33298617|t=2021. Repurposed Tocilizumab in Patients with Severe COVID-19.|pdf=|usr=}}
{{tp|p=33837054|t=2021. IL-6 modulation for COVID-19: the right patients at the right time?|pdf=|usr=}}
{{tp|p=34029628|t=2021. Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?|pdf=|usr=}}
{{tp|p=34052239|t=2021. Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33992687|t=2021. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.|pdf=|usr=}}
{{tp|p=34020215|t=2021. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33341481|t=2021. Impact of repurposed drugs on the symptomatic COVID-19 patients.|pdf=|usr=}}
{{tp|p=34045883|t=2021. Fat-Soluble Vitamins and the Current Global Pandemic of COVID-19: Evidence-Based Efficacy from Literature Review.|pdf=|usr=}}
{{tp|p=33833542|t=2021. Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection.|pdf=|usr=}}
{{tp|p=33983065|t=2021. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.|pdf=|usr=}}
{{tp|p=33906526|t=2021. Oxygen saturation improved with nitrate-based nutritional formula in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33349611|t=2021. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.|pdf=|usr=}}
{{tp|p=33847265|t=2021. COVID-19 and TEN treated with IVIG and Total plasma exchange. Simultaneous systemic treatment for both diseases.|pdf=|usr=}}
{{tp|p=34105382|t=2021. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.|pdf=|usr=}}
{{tp|p=34054244|t=2021. Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19.|pdf=|usr=}}
{{tp|p=34010403|t=2021. Tocilizumab in the treatment of COVID-19 - a meta-analysis.|pdf=|usr=}}
{{tp|p=33989420|t=2021. Corticosteroids for treating mild COVID-19: Opening the floodgates of therapeutic misadventure.|pdf=|usr=}}
{{tp|p=33988903|t=2021. Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity.|pdf=|usr=}}
{{tp|p=33874878|t=2021. Probiotics/ prebiotics in viral respiratory infections: implication for emerging pathogens.|pdf=|usr=}}
{{tp|p=34009761|t=2021. Inefficacite de l'ivermectine sur les symptomes de Covid-19 leger.|pdf=|usr=}}
{{tp|p=33881236|t=2021. Covid-19 - vitamine D - traitement de l'osteoporose.|pdf=|usr=}}
{{tp|p=34083449|t=2021. Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets.|pdf=|usr=}}
{{tp|p=34103349|t=2021. Senolytics reduce coronavirus-related mortality in old mice.|pdf=|usr=}}
{{tp|p=33843825|t=2021. Intrapleural Steroid Instillation for Critically Ill Patients With Covid-19 Severe Adult Respiratory Distress Syndrome.|pdf=|usr=}}

{{tp|p=34020394|t=2021. Insights on the mechanisms of action of ozone in the medical therapy against COVID-19.|pdf=|usr=}}
{{tp|p=34020392|t=2021. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment.|pdf=|usr=}}
{{tp|p=34015598|t=2021. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.|pdf=|usr=}}
{{tp|p=33984718|t=2021. A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial.|pdf=|usr=}}
{{tp|p=33882442|t=2021. Immunopharmacological perspective on zinc in SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33310665|t=2021. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study.|pdf=|usr=}}
{{tp|p=33348292|t=2021. Interferon-inducer antivirals: Potential candidates to combat COVID-19.|pdf=|usr=}}
{{tp|p=33338863|t=2021. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.|pdf=|usr=}}
{{tp|p=33930705|t=2021. The role of vitamin D in reducing SARS-CoV-2 infection: An update.|pdf=|usr=}}
{{tp|p=33838224|t=2021. Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.|pdf=|usr=}}
{{tp|p=33370568|t=2021. Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives.|pdf=|usr=}}
{{tp|p=33338559|t=2021. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.|pdf=|usr=}}
{{tp|p=33321211|t=2021. Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.|pdf=|usr=}}
{{tp|p=33609720|t=2021. Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".|pdf=|usr=}}
{{tp|p=33609717|t=2021. Perceived efficacy of hydroxychloroquine in observational studies: Results of the confounding effect of "goals of care".|pdf=|usr=}}
{{tp|p=34048833|t=2021. Classification, structure and mechanism of antiviral polysaccharides derived from edible and medicinal fungus.|pdf=|usr=}}
{{tp|p=33930442|t=2021. Chitin and chitosan as tools to combat COVID-19: A triple approach.|pdf=|usr=}}
{{tp|p=33915212|t=2021. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy.|pdf=|usr=}}
{{tp|p=33901557|t=2021. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro).|pdf=|usr=}}
{{tp|p=34051259|t=2021. Ethyl cellulose coated sustained release aspirin spherules for treating COVID-19: DOE led rapid optimization using arbitrary interface; applicable for emergency situations.|pdf=|usr=}}
{{tp|p=33309661|t=2021. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.|pdf=|usr=}}
{{tp|p=33907519|t=2021. In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor.|pdf=|usr=}}
{{tp|p=33907517|t=2021. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.|pdf=|usr=}}
{{tp|p=34000267|t=2021. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.|pdf=|usr=}}
{{tp|p=33895839|t=2021. COVID-19 Trial Graph: A Linked Graph for COVID-19 Clinical Trials.|pdf=|usr=}}
{{tp|p=33880524|t=2021. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.|pdf=|usr=}}
{{tp|p=33712855|t=2021. Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C.|pdf=|usr=}}
{{tp|p=33338232|t=2021. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.|pdf=|usr=}}
{{tp|p=33976504|t=2021. Potential for supportive Ayurvedic care in hypoxemic COVID-19 patients.|pdf=|usr=}}
{{tp|p=34054248|t=2021. "Standalone Ayurvedic Intervention with Home Quarantine in COVID-19 - Outcomes of Clinical Practice".|pdf=|usr=}}
{{tp|p=34054247|t=2021. Immune status determined as per guidelines of Ayurveda found associated with clinical outcomes of COVID-19 disease - Results of a cross-sectional pilot study.|pdf=|usr=}}
{{tp|p=34054246|t=2021. Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with M(Pro) of SARS-CoV-2 through in silico analysis.|pdf=|usr=}}
{{tp|p=34024691|t=2021. A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only Ayurvedic Medicines.|pdf=|usr=}}
{{tp|p=33654345|t=2021. In silico evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33897204|t=2021. A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India.|pdf=|usr=}}
{{tp|p=34082895|t=2021. Significance of AYUSH: India's first line of defence against COVID-19.|pdf=|usr=}}
{{tp|p=33989635|t=2021. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.|pdf=|usr=}}
{{tp|p=33895135|t=2021. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells.|pdf=|usr=}}
{{tp|p=33891947|t=2021. Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era.|pdf=|usr=}}
{{tp|p=34052441|t=2021. Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations.|pdf=|usr=}}
{{tp|p=33856612|t=2021. A COVID moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy.|pdf=|usr=}}
{{tp|p=33950784|t=2021. Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications.|pdf=|usr=}}
{{tp|p=33949286|t=2021. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33949279|t=2021. Antivirals virtual screening to SARS-CoV-2 non-structural proteins.|pdf=|usr=}}
{{tp|p=33939590|t=2021. In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2.|pdf=|usr=}}
{{tp|p=34033727|t=2021. How to face COVID-19: proposed treatments based on remdesivir and hydroxychloroquine in the presence of zinc sulfate. Docking/DFT/POM structural analysis.|pdf=|usr=}}
{{tp|p=34032180|t=2021. Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication.|pdf=|usr=}}
{{tp|p=34018907|t=2021. Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking.|pdf=|usr=}}
{{tp|p=34014150|t=2021. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.|pdf=|usr=}}
{{tp|p=33998954|t=2021. A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction.|pdf=|usr=}}
{{tp|p=33988079|t=2021. Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytocompounds against SARS-CoV-2 proteins.|pdf=|usr=}}
{{tp|p=33988066|t=2021. Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs.|pdf=|usr=}}
{{tp|p=33998950|t=2021. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.|pdf=|usr=}}
{{tp|p=33970798|t=2021. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.|pdf=|usr=}}
{{tp|p=34062110|t=2021. Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications.|pdf=|usr=}}
{{tp|p=34060418|t=2021. Molecular modeling of potent novel sulfonamide derivatives as non-peptide small molecule anti-COVID 19 agents.|pdf=|usr=}}
{{tp|p=33826483|t=2021. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.|pdf=|usr=}}
{{tp|p=33896392|t=2021. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.|pdf=|usr=}}
{{tp|p=33879035|t=2021. The in silico mechanism of hVKOR interaction with acetaminophen and its metabolite, as well as N-acetyl cysteine: caution on application in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33847241|t=2021. Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein.|pdf=|usr=}}
{{tp|p=33843474|t=2021. Elucidation of the inhibitory activity of ivermectin with host nuclear importin alpha and several SARS-CoV-2 targets.|pdf=|usr=}}
{{tp|p=34068104|t=2021. Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34028178|t=2021. Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design.|pdf=|usr=}}
{{tp|p=33336936|t=2021. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.|pdf=|usr=}}
{{tp|p=33829781|t=2021. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro.|pdf=|usr=}}
{{tp|p=34047191|t=2021. Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro.|pdf=|usr=}}
{{tp|p=34052564|t=2021. Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum.|pdf=|usr=}}
{{tp|p=33310480|t=2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.|pdf=|usr=}}
{{tp|p=34101091|t=2021. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-beta.|pdf=|usr=}}
{{tp|p=34009544|t=2021. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.|pdf=|usr=}}
{{tp|p=33844653|t=2021. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice.|pdf=|usr=}}
{{tp|p=33974559|t=2021. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.|pdf=|usr=}}
{{tp|p=33306484|t=2021. BCG vaccination in health care providers and the protection against COVID-19.|pdf=|usr=}}
{{tp|p=33320842|t=2021. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.|pdf=|usr=}}
{{tp|p=33994121|t=2021. Statins in COVID-19 infection: A rehash of old themes or truly a new hope?|pdf=|usr=}}
{{tp|p=34071293|t=2021. Vitamin D Levels in COVID-19 Outpatients from Western Mexico: Clinical Correlation and Effect of Its Supplementation.|pdf=|usr=}}
{{tp|p=34070628|t=2021. Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.|pdf=|usr=}}
{{tp|p=34069355|t=2021. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease.|pdf=|usr=}}
{{tp|p=34068847|t=2021. Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33918563|t=2021. Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6.|pdf=|usr=}}
{{tp|p=33917093|t=2021. Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19.|pdf=|usr=}}
{{tp|p=33916281|t=2021. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33915784|t=2021. Adjunctive Use of Statins for COVID-19.|pdf=|usr=}}
{{tp|p=33992179|t=2021. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?|pdf=|usr=}}
{{tp|p=34007812|t=2021. Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=34007810|t=2021. Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate.|pdf=|usr=}}
{{tp|p=34027204|t=2021. Interleukin-13 as a target to alleviate severe coronavirus disease 2019 and restore lung homeostasis.|pdf=|usr=}}
{{tp|p=33889318|t=2021. Experimental therapies under investigation for COVID-19.|pdf=|usr=}}
{{tp|p=33887951|t=2021. Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33622611|t=2021. Cheap and simple, could it get even cooler? Mild hypothermia and COVID-19.|pdf=|usr=}}
{{tp|p=33583631|t=2021. Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19.|pdf=|usr=}}
{{tp|p=33884425|t=2021. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry.|pdf=|usr=}}
{{tp|p=33331120|t=2021. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?|pdf=|usr=}}
{{tp|p=33816359|t=2021. Vitamin D and COVID-19: is there a role?|pdf=|usr=}}
{{tp|p=33816358|t=2021. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.|pdf=|usr=}}
{{tp|p=33649708|t=2021. The pulmonary route as a way to drug repositioning in COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33617141|t=2021. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33688540|t=2021. Review of investigational drugs for coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=34075313|t=2021. Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment Favipiravir in the presence of coadministered drugs.|pdf=|usr=}}
{{tp|p=33353811|t=2021. Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity.|pdf=|usr=}}
{{tp|p=33840080|t=2021. Vitamin D and Vitamin D binding protein: the inseparable duo in COVID-19.|pdf=|usr=}}
{{tp|p=34053008|t=2021. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience.|pdf=|usr=}}
{{tp|p=33980119|t=2021. Flavonoids as inhibitors of human neutrophil elastase.|pdf=|usr=}}
{{tp|p=34044222|t=2021. A literature review on beneficial role of vitamins and trace elements: Evidence from published clinical studies.|pdf=|usr=}}
{{tp|p=34026584|t=2021. Calendulaglycoside A Showing Potential Activity Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and SAR Studies.|pdf=|usr=}}
{{tp|p=34099976|t=2021. In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors.|pdf=|usr=}}
{{tp|p=33868970|t=2021. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.|pdf=|usr=}}
{{tp|p=33778462|t=2021. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.|pdf=|usr=}}
{{tp|p=33971907|t=2021. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.|pdf=|usr=}}
{{tp|p=33781275|t=2021. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.|pdf=|usr=}}
{{tp|p=33902635|t=2021. Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study.|pdf=|usr=}}
{{tp|p=33888147|t=2021. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.|pdf=|usr=}}

{{tp|p=34026595|t=2021. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.|pdf=|usr=}}
{{tp|p=34099209|t=2021. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?|pdf=|usr=}}
{{tp|p=33985598|t=2021. Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness.|pdf=|usr=}}
{{tp|p=33974479|t=2021. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=34024240|t=2021. A short course of corticosteroids reduces the risk of mechanical ventilation and death in patients with moderate to severe COVID 19 pneumonia: results of a retrospective monocentric cohort.|pdf=|usr=}}
{{tp|p=34001244|t=2021. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33874998|t=2021. Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.|pdf=|usr=}}
{{tp|p=34067822|t=2021. Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.|pdf=|usr=}}
{{tp|p=33928532|t=2021. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.|pdf=|usr=}}
{{tp|p=33914266|t=2021. Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.|pdf=|usr=}}
{{tp|p=33826106|t=2021. Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=34040397|t=2021. Network Analysis of Herbs Recommended for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33880043|t=2021. The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data.|pdf=|usr=}}
{{tp|p=34089909|t=2021. Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34052418|t=2021. Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.|pdf=|usr=}}
{{tp|p=33907516|t=2021. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers.|pdf=|usr=}}
{{tp|p=33907515|t=2021. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19.|pdf=|usr=}}
{{tp|p=33907512|t=2021. Development and application of therapeutic antibodies against COVID-19.|pdf=|usr=}}
{{tp|p=33332726|t=2021. Dexamethasone vs COVID-19: An experimental study in line with the preliminary findings of a large trial.|pdf=|usr=}}
{{tp|p=33300221|t=2021. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation.|pdf=|usr=}}
{{tp|p=34064793|t=2021. Does Trypsin Oral Spray (Viruprotect((R))/ColdZyme((R))) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union.|pdf=|usr=}}
{{tp|p=33801759|t=2021. Vitamin D Levels Are Reduced at the Time of Hospital Admission in Sicilian SARS-CoV-2-Positive Patients.|pdf=|usr=}}
{{tp|p=33924038|t=2021. Impact of COVID-19 Lockdown on Sun Exposure of UK Office Workers.|pdf=|usr=}}
{{tp|p=33919644|t=2021. COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan.|pdf=|usr=}}
{{tp|p=33359949|t=2021. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33940189|t=2021. Does vitamin D serum level affect prognosis of COVID-19 patients?|pdf=|usr=}}
{{tp|p=33901652|t=2021. COVID-19 chemoprevention.|pdf=|usr=}}
{{tp|p=33892191|t=2021. Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman.|pdf=|usr=}}
{{tp|p=34087484|t=2021. Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study.|pdf=|usr=}}
{{tp|p=33878462|t=2021. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial.|pdf=|usr=}}
{{tp|p=33333254|t=2021. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study.|pdf=|usr=}}
{{tp|p=33333252|t=2021. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.|pdf=|usr=}}
{{tp|p=33333250|t=2021. A high-throughput drug screening strategy against coronaviruses.|pdf=|usr=}}
{{tp|p=33316389|t=2021. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.|pdf=|usr=}}
{{tp|p=33310109|t=2021. Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".|pdf=|usr=}}
{{tp|p=33310107|t=2021. Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".|pdf=|usr=}}
{{tp|p=33310106|t=2021. More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.|pdf=|usr=}}
{{tp|p=34066560|t=2021. Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.|pdf=|usr=}}
{{tp|p=34073529|t=2021. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?|pdf=|usr=}}
{{tp|p=34067243|t=2021. Possible Beneficial Actions of Caffeine in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34063964|t=2021. Existing Drugs Considered as Promising in COVID-19 Therapy.|pdf=|usr=}}
{{tp|p=34065735|t=2021. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.|pdf=|usr=}}
{{tp|p=33917321|t=2021. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.|pdf=|usr=}}
{{tp|p=33920709|t=2021. COVID-19: Direct and Indirect Mechanisms of Statins.|pdf=|usr=}}
{{tp|p=33920748|t=2021. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33921228|t=2021. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.|pdf=|usr=}}
{{tp|p=33867899|t=2021. In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins.|pdf=|usr=}}
{{tp|p=33850482|t=2021. Identification of Potential Peptide Inhibitors of ACE-2 Target of SARS-CoV-2 from Buckwheat & Quinoa.|pdf=|usr=}}
{{tp|p=33880115|t=2021. Potential Antioxidative, Anti-inflammatory and Immunomodulatory Effects of Ghrelin, an Endogenous Peptide from the Stomach in SARS-CoV2 Infection.|pdf=|usr=}}
{{tp|p=33373651|t=2021. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.|pdf=|usr=}}
{{tp|p=33902990|t=2021. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=33814353|t=2021. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.|pdf=|usr=}}
{{tp|p=33956648|t=2021. Nutritional status is closely related to the severity of COVID-19: a multi-center retrospective study.|pdf=|usr=}}
{{tp|p=33367731|t=2021. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.|pdf=|usr=}}
{{tp|p=33885811|t=2021. Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19.|pdf=|usr=}}
{{tp|p=33961695|t=2021. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.|pdf=|usr=}}
{{tp|p=33866129|t=2021. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.|pdf=|usr=}}
{{tp|p=33857725|t=2021. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.|pdf=|usr=}}
{{tp|p=33848890|t=2021. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (M(pro)) with pharmacokinetics and toxicological properties.|pdf=|usr=}}
{{tp|p=33984091|t=2021. A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.|pdf=|usr=}}
{{tp|p=33877845|t=2021. Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease.|pdf=|usr=}}
{{tp|p=34081439|t=2021. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.|pdf=|usr=}}
{{tp|p=33929200|t=2021. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human beta-Coronavirus Infection.|pdf=|usr=}}
{{tp|p=33872498|t=2021. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34026588|t=2021. Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease.|pdf=|usr=}}
{{tp|p=34090821|t=2021. Good response of low-dose steroid in a patient with COVID-19 pneumonia and autoimmune disease.|pdf=|usr=}}
{{tp|p=33373642|t=2021. Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.|pdf=|usr=}}
{{tp|p=33333424|t=2021. Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking, molecular dynamics simulation and MM/GBSA study.|pdf=|usr=}}
{{tp|p=33798836|t=2021. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.|pdf=|usr=}}
{{tp|p=33933885|t=2021. Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33892297|t=2021. In silico approach for identifying natural lead molecules against SARS-COV-2.|pdf=|usr=}}
{{tp|p=33994607|t=2021. Inhibition of SARS-CoV-2 reproduction using Boswellia carterii: A theoretical study.|pdf=|usr=}}
{{tp|p=33746318|t=2021. Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib.|pdf=|usr=}}
{{tp|p=33846661|t=2021. Construction, petro-collecting/dispersing capacities, antimicrobial activity, and molecular docking study of new cationic surfactant-sulfonamide conjugates.|pdf=|usr=}}
{{tp|p=34031621|t=2021. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists.|pdf=|usr=}}
{{tp|p=33903781|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part III: A green protocol for facile synthesis of complexes with TCNQ, DDQ, and TFQ acceptors.|pdf=|usr=}}
{{tp|p=33879934|t=2021. Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.|pdf=|usr=}}
{{tp|p=33963942|t=2021. Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach.|pdf=|usr=}}
{{tp|p=34057647|t=2021. Plausible blockers of Spike RBD in SARS-CoV2-molecular design and underlying interaction dynamics from high-level structural descriptors.|pdf=|usr=}}
{{tp|p=33864532|t=2021. Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19.|pdf=|usr=}}
{{tp|p=33903779|t=2021. Synthesis, X-ray crystal structure, IR and Raman spectroscopic analysis, quantum chemical computational and molecular docking studies on hydrazone-pyridine compound: As an insight into the inhibitor capacity of main protease of SARS-CoV2.|pdf=|usr=}}
{{tp|p=33903778|t=2021. In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis.|pdf=|usr=}}
{{tp|p=33903777|t=2021. New alpha-Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33967344|t=2021. Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches.|pdf=|usr=}}
{{tp|p=33967343|t=2021. In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2(Covid-19) main protease by using molecular docking and dynamic analyses.|pdf=|usr=}}
{{tp|p=34007088|t=2021. Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells.|pdf=|usr=}}
{{tp|p=34054142|t=2021. DFT, molecular docking and molecular dynamics simulation studies on some newly introduced natural products for their potential use against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34031619|t=2021. Chemical reactivities and molecular docking studies of parthenolide with the main protease of HEP-G2 and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33846658|t=2021. Synthesis, antimicrobial activity, density functional modelling and molecular docking with COVID-19 main protease studies of benzoxazole derivative: 2-(p-chloro-benzyl)-5-[3-(4-ethly-1-piperazynl) propionamido]-benzoxazole.|pdf=|usr=}}
{{tp|p=33840836|t=2021. The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33840835|t=2021. Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33867575|t=2021. Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins.|pdf=|usr=}}
{{tp|p=33928494|t=2021. Screening for inhibitory effects of crude drugs on furin-like enzymatic activities.|pdf=|usr=}}
{{tp|p=33352046|t=2021. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33844528|t=2021. Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives.|pdf=|usr=}}
{{tp|p=33884222|t=2021. Chemo-Preventive Effect of Vegetables and Fruits Consumption on the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33949642|t=2021. Letter to the Editor: Challenges Providing Nutrition Care during the COVID-19 Pandemic: Canadian Dietitian Perspectives.|pdf=|usr=}}
{{tp|p=33367467|t=2021. A Correlation Analysis between the Nutritional Status and Prognosis of COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33306130|t=2021. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33842018|t=2021. Reducing SARS-CoV-2 pathological protein activity with small molecules.|pdf=|usr=}}
{{tp|p=34084043|t=2021. Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?|pdf=|usr=}}
{{tp|p=33831737|t=2021. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers.|pdf=|usr=}}
{{tp|p=34048671|t=2021. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34048669|t=2021. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=34048668|t=2021. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33939951|t=2021. Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.|pdf=|usr=}}
{{tp|p=33912505|t=2020. Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=34091026|t=2021. The relationship between 25(OH) vitamin D levels and COVID-19 onset and disease course in Spanish patients.|pdf=|usr=}}
{{tp|p=33864925|t=2021. Learning from previous methodological pitfalls to propose well-designed trials on vitamin D in COVID-19.|pdf=|usr=}}
{{tp|p=34059065|t=2021. Exosomes contribution in COVID-19 patients' treatment.|pdf=|usr=}}
{{tp|p=33853637|t=2021. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells.|pdf=|usr=}}
{{tp|p=33968608|t=2021. The face mask-touching behavior during the COVID-19 pandemic: Observational study of public transportation users in the greater Paris region: The French-mask-touch study.|pdf=|usr=}}

{{tp|p=34033406|t=2021. Tocilizumab|pdf=|usr=}}
{{tp|p=34033367|t=2021. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)|pdf=|usr=}}
{{tp|p=34033365|t=2021. Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations|pdf=|usr=}}
{{tp|p=34097371|t=2021. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations (EUAs)|pdf=|usr=}}
{{tp|p=34009769|t=2020. Science Brief: COVID-19 Vaccines and Vaccination|pdf=|usr=}}
{{tp|p=34014630|t=2012. Covid-19 Drugs|pdf=|usr=}}
{{tp|p=34014629|t=2012. Covid-19 Vaccines|pdf=|usr=}}
{{tp|p=34014628|t=2012. Covid-19 Monoclonal Antibodies: Monoclonal Antibodies to SARS-CoV-2|pdf=|usr=}}
{{tp|p=31643344|t=2012. Baricitinib|pdf=|usr=}}
{{tp|p=33835300|t=2021. Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.|pdf=|usr=}}
{{tp|p=33985872|t=2021. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review.|pdf=|usr=}}
{{tp|p=33930273|t=2021. Glycyrrhizic Acid Nanoparticles as Antiviral and Anti-inflammatory Agents for COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33378177|t=2021. Cracking the Chloroquine Conundrum: The Application of Defective UiO-66 Metal-Organic Framework Materials to Prevent the Onset of Heart Defects-In Vivo and In Vitro.|pdf=|usr=}}
{{tp|p=34075346|t=2021. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.|pdf=|usr=}}
{{tp|p=34075345|t=2021. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.|pdf=|usr=}}
{{tp|p=34075344|t=2021. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=34056095|t=2021. Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.|pdf=|usr=}}
{{tp|p=34056089|t=2021. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.|pdf=|usr=}}
{{tp|p=34056083|t=2021. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.|pdf=|usr=}}
{{tp|p=33979123|t=2021. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33849267|t=2021. Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone.|pdf=|usr=}}
{{tp|p=33876632|t=2021. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.|pdf=|usr=}}
{{tp|p=33854700|t=2021. Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33850605|t=2021. Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain.|pdf=|usr=}}
{{tp|p=33373194|t=2021. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.|pdf=|usr=}}
{{tp|p=34056406|t=2021. Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19.|pdf=|usr=}}
{{tp|p=34056192|t=2021. Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.|pdf=|usr=}}
{{tp|p=33855277|t=2021. Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir.|pdf=|usr=}}
{{tp|p=33855276|t=2021. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.|pdf=|usr=}}
{{tp|p=33855275|t=2021. Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications.|pdf=|usr=}}
{{tp|p=34018145|t=2021. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine.|pdf=|usr=}}
{{tp|p=34002386|t=2021. Neurological side effects of COVID-19 vaccines are rare.|pdf=|usr=}}
{{tp|p=34002379|t=2021. SARS-CoV-2 vaccines are not free of neurological side effects.|pdf=|usr=}}
{{tp|p=34002130|t=2021. SARS-CoV-2 cell entry and targeted antiviral development.|pdf=|usr=}}
{{tp|p=33850275|t=2021. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.|pdf=|usr=}}
{{tp|p=33931765|t=2021. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.|pdf=|usr=}}
{{tp|p=33907306|t=2021. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.|pdf=|usr=}}
{{tp|p=33350096|t=2021. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.|pdf=|usr=}}
{{tp|p=34012162|t=2021. Familiar dermatologic drugs as therapies for COVID-19.|pdf=|usr=}}
{{tp|p=33880039|t=2021. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.|pdf=|usr=}}
{{tp|p=33359141|t=2021. COVID-19 vaccines: The status and perspectives in delivery points of view.|pdf=|usr=}}
{{tp|p=33340620|t=2021. Non-viral COVID-19 vaccine delivery systems.|pdf=|usr=}}
{{tp|p=33316346|t=2021. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=}}
{{tp|p=33309815|t=2021. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.|pdf=|usr=}}
{{tp|p=34060150|t=2021. Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2.|pdf=|usr=}}
{{tp|p=34022675|t=2021. Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis.|pdf=|usr=}}
{{tp|p=33966265|t=2021. Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?|pdf=|usr=}}
{{tp|p=33966262|t=2021. The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration - a metaanalysis.|pdf=|usr=}}
{{tp|p=33966260|t=2021. A clinical profile and factors associated with severity of the disease among Polish patients hospitalized due to COVID-19 - an observational study.|pdf=|usr=}}
{{tp|p=33881163|t=2021. Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!|pdf=|usr=}}
{{tp|p=33871042|t=2021. Timing of Anti-viral therapy in COVID-19: Key to success.|pdf=|usr=}}
{{tp|p=33850691|t=2021. Nitric Oxide to Fight Viral Infections.|pdf=|usr=}}
{{tp|p=34075554|t=2021. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.|pdf=|usr=}}
{{tp|p=34028041|t=2021. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!|pdf=|usr=}}
{{tp|p=33948956|t=2021. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced.|pdf=|usr=}}
{{tp|p=33837568|t=2021. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.|pdf=|usr=}}
{{tp|p=33993490|t=2021. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS CoV2 infection and long COVID.|pdf=|usr=}}
{{tp|p=34020451|t=2021. Influence of vitamin D status on hospital length of stay and prognosis in hospitalized patients with moderate to severe COVID-19: a multicenter prospective cohort study.|pdf=|usr=}}
{{tp|p=34057236|t=2021. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor.|pdf=|usr=}}
{{tp|p=33837984|t=2021. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34057243|t=2021. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.|pdf=|usr=}}
{{tp|p=33939851|t=2021. Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.|pdf=|usr=}}
{{tp|p=33738273|t=2020. Anti-Infective, Anti-Inflammatory, and Immunomodulatory Properties of Breast Milk Factors for the Protection of Infants in the Pandemic From COVID-19.|pdf=|usr=}}
{{tp|p=34095323|t=2021. Potent phytochemicals against COVID-19 infection from phyto-materials used as antivirals in complementary medicines: a review.|pdf=|usr=}}
{{tp|p=34099962|t=2021. Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery.|pdf=|usr=}}
{{tp|p=34055031|t=2021. Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series.|pdf=|usr=}}
{{tp|p=33891952|t=2021. Reply.|pdf=|usr=}}
{{tp|p=33340538|t=2021. Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection.|pdf=|usr=}}
{{tp|p=34045093|t=2021. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19.|pdf=|usr=}}
{{tp|p=33346100|t=2021. Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach.|pdf=|usr=}}
{{tp|p=33887367|t=2021. Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data.|pdf=|usr=}}
{{tp|p=34073716|t=2021. Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.|pdf=|usr=}}
{{tp|p=33321203|t=2021. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33937567|t=2021. Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan.|pdf=|usr=}}
{{tp|p=33987628|t=2021. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective.|pdf=|usr=}}
{{tp|p=34104701|t=2021. Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19.|pdf=|usr=}}
{{tp|p=34026493|t=2021. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease.|pdf=|usr=}}
{{tp|p=34007917|t=2021. Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.|pdf=|usr=}}
{{tp|p=33824915|t=2021. Design and identification of novel annomontine analogues against SARS-CoV-2: An in-silico approach.|pdf=|usr=}}
{{tp|p=33903854|t=2021. Convalescent plasma therapy - a silver lining for COVID-19 management?|pdf=|usr=}}
{{tp|p=33905094|t=2021. Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy.|pdf=|usr=}}
{{tp|p=33974497|t=2021. Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.|pdf=|usr=}}
{{tp|p=33913801|t=2021. Impact of influenza vaccination on the risk of SARS-CoV-2 infection in a middle-aged group of people.|pdf=|usr=}}
{{tp|p=33836142|t=2021. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.|pdf=|usr=}}
{{tp|p=33834387|t=2021. MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.|pdf=|usr=}}
{{tp|p=34018464|t=2021. Anti-IgE monoclonal antibodies as potential treatment in COVID-19.|pdf=|usr=}}
{{tp|p=34015982|t=2021. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.|pdf=|usr=}}
{{tp|p=34057871|t=2021. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.|pdf=|usr=}}
{{tp|p=33906375|t=2021. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).|pdf=|usr=}}
{{tp|p=33842191|t=2021. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.|pdf=|usr=}}
{{tp|p=33842190|t=2021. In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.|pdf=|usr=}}
{{tp|p=34045820|t=2021. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19.|pdf=|usr=}}
{{tp|p=34045817|t=2021. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.|pdf=|usr=}}
{{tp|p=34045812|t=2021. Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33846691|t=2021. Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.|pdf=|usr=}}
{{tp|p=33973204|t=2021. Challenges of Cellular Therapy During the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33973199|t=2021. The COVID-19 Vaccine Landscape.|pdf=|usr=}}
{{tp|p=33973198|t=2021. Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management.|pdf=|usr=}}
{{tp|p=33973197|t=2021. Dietary Supplements for COVID-19.|pdf=|usr=}}
{{tp|p=33973196|t=2021. Nutrition and Immunity in COVID-19.|pdf=|usr=}}
{{tp|p=33973194|t=2021. Immune-Based Therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33861442|t=2021. Possible Mechanisms and Special Clinical Considerations of Curcumin Supplementation in Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33993131|t=2021. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.|pdf=|usr=}}
{{tp|p=34009000|t=2021. Frequency and Characteristics of Nodal and Deltoid FDG and 11C-Choline Uptake on PET Imaging Performed After COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33980347|t=2021. Is nutraceutical supplementation appropriate for COVID-19 management?|pdf=|usr=}}
{{tp|p=33357261|t=2021. The war on infectious diseases: COVID-19 vaccines and the public: Challenges and solutions.|pdf=|usr=}}
{{tp|p=33373323|t=2021. Time to Enhance Immunity via Functional Foods and Supplements: Hope for SARS-CoV-2 Outbreak.|pdf=|usr=}}
{{tp|p=33891569|t=2021. Neem (Azadirachta Indica A. Juss) Capsules for Prophylaxis of COVID-19 Infection: A Pilot, Double-Blind, Randomized Controlled Trial.|pdf=|usr=}}
{{tp|p=34060795|t=2021. Case Report: Thrombotic Thrombocytopenia after COVID-19 Janssen Vaccination.|pdf=|usr=}}
{{tp|p=33853498|t=2021. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19.|pdf=|usr=}}
{{tp|p=34047304|t=2021. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.|pdf=|usr=}}
{{tp|p=33982938|t=2021. Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.|pdf=|usr=}}

{{tp|p=34038639|t=2021. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp.|pdf=|usr=}}
{{tp|p=33988136|t=2021. Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma.|pdf=|usr=}}
{{tp|p=33898162|t=2021. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI.|pdf=|usr=}}
{{tp|p=33962863|t=2021. Allergy to COVID-19 vaccines: A current update.|pdf=|usr=}}
{{tp|p=33842829|t=2021. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA).|pdf=|usr=}}
{{tp|p=33316045|t=2021. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.|pdf=|usr=}}
{{tp|p=33994051|t=2021. COVID-19 vaccine adverse reactions bring patients to emergency departments.|pdf=|usr=}}
{{tp|p=33980419|t=2021. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.|pdf=|usr=}}
{{tp|p=34062319|t=2021. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34059386|t=2021. Extending the clinical spectrum of thrombotic thrombocytopenic syndrome attributable to adenovirus-based vaccines for Covid-19.|pdf=|usr=}}
{{tp|p=33348222|t=2021. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.|pdf=|usr=}}
{{tp|p=33896653|t=2021. Thymosin a1 use is not associated with reduced COVID-19 mortality.|pdf=|usr=}}
{{tp|p=33847737|t=2021. Safety of Tenofovir Disoproxil Fumarate (TDF) for Pregnant Women facing the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33950198|t=2021. Peripheral infiltration of remdesivir in 3 patients with COVID-19: Case series and discussion.|pdf=|usr=}}
{{tp|p=33955454|t=2021. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout.|pdf=|usr=}}
{{tp|p=34023417|t=2021. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33839200|t=2021. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34019949|t=2021. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients.|pdf=|usr=}}
{{tp|p=33992727|t=2021. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34059207|t=2021. Virucidal mouth rinses for patients during the coronavirus disease 2019 outbreak.|pdf=|usr=}}
{{tp|p=33894177|t=2021. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators.|pdf=|usr=}}
{{tp|p=33949212|t=2021. The effect of estrogen in coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33566663|t=2021. Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries.|pdf=|usr=}}
{{tp|p=32955926|t=2021. Role of IL-6 in Severe Inflammation.|pdf=|usr=}}
{{tp|p=34085760|t=2021. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-March 2021.|pdf=|usr=}}
{{tp|p=34080285|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely.|pdf=|usr=}}
{{tp|p=34058052|t=2021. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients.|pdf=|usr=}}
{{tp|p=34043872|t=2021. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients.|pdf=|usr=}}
{{tp|p=34036720|t=2021. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.|pdf=|usr=}}
{{tp|p=33866672|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.|pdf=|usr=}}
{{tp|p=33864722|t=2021. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.|pdf=|usr=}}
{{tp|p=33829628|t=2021. The future of SARS-CoV-2 vaccines in transplant recipients: To be determined.|pdf=|usr=}}
{{tp|p=33890410|t=2021. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=33950300|t=2021. Human cell receptors: potential drug targets to combat COVID-19.|pdf=|usr=}}
{{tp|p=33995537|t=2021. EVOLUCION DEL INTERVALO QTC EN PACIENTES CON INFECCION SARS-COV-2 TRATADOS CON FARMACOS ANTIVIRALES( lozenge).|pdf=|usr=}}
{{tp|p=33946037|t=2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.|pdf=|usr=}}
{{tp|p=33895471|t=2021. COVID-19 vaccines surveillance in France: a global response to a major national challenge.|pdf=|usr=}}
{{tp|p=34033927|t=2021. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience.|pdf=|usr=}}
{{tp|p=33901708|t=2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.|pdf=|usr=}}
{{tp|p=33867032|t=2021. First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode.|pdf=|usr=}}
{{tp|p=33350010|t=2021. A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33860605|t=2021. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions.|pdf=|usr=}}
{{tp|p=33915014|t=2021. Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication.|pdf=|usr=}}
{{tp|p=34022388|t=2021. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency.|pdf=|usr=}}
{{tp|p=33838338|t=2021. Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States.|pdf=|usr=}}
{{tp|p=33962029|t=2021. Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination.|pdf=|usr=}}
{{tp|p=34020659|t=2021. Repurposing of antibiotics for clinical management of COVID-19: a narrative review.|pdf=|usr=}}
{{tp|p=34030782|t=2021. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=33349491|t=2021. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?|pdf=|usr=}}
{{tp|p=33940219|t=2021. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis.|pdf=|usr=}}
{{tp|p=34057642|t=2021. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study.|pdf=|usr=}}
{{tp|p=33956361|t=2021. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.|pdf=|usr=}}
{{tp|p=34035003|t=2021. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.|pdf=|usr=}}
{{tp|p=33903110|t=2021. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.|pdf=|usr=}}
{{tp|p=34097489|t=2021. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.|pdf=|usr=}}
{{tp|p=34042319|t=2021. Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases.|pdf=|usr=}}
{{tp|p=34042308|t=2021. Reply.|pdf=|usr=}}
{{tp|p=33857328|t=2021. Can ketone bodies inactivate coronavirus spike protein? The potential of biocidal agents against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33938041|t=2021. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33338375|t=2021. Could Simultaneous Nasal and Oral Irrigation Be a Nontherapeutic Tool against SARS-CoV-2?|pdf=|usr=}}
{{tp|p=33860219|t=2021. Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection.|pdf=|usr=}}
{{tp|p=33860218|t=2021. SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen.|pdf=|usr=}}
{{tp|p=33308005|t=2021. Bail-out extracorporeal membrane oxygenation for hydroxychloroquine intoxication: a warning for COVID-19 health-care givers.|pdf=|usr=}}
{{tp|p=34008482|t=2021. Ethical reflections on Covid-19 vaccines.|pdf=|usr=}}
{{tp|p=33428805|t=2021. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.|pdf=|usr=}}
{{tp|p=33350698|t=2021. Remdesivir in The Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33350691|t=2021. Remdesivir Approved to Treat COVID-19 Amid Controversy.|pdf=|usr=}}
{{tp|p=33932943|t=2021. COVID-19 Vaccine Considerations during Pregnancy and Lactation.|pdf=|usr=}}
{{tp|p=34014798|t=2021. Interleukin-6 Inhibition Reduces Neuronal Injury In A Murine Model of Ventilator-Induced Lung Injury.|pdf=|usr=}}
{{tp|p=33961754|t=2021. Therapeutic Application of Alpha-1 Antitrypsin in COVID-19.|pdf=|usr=}}
{{tp|p=33852488|t=2021. Arrhythmias in Patients With Coronavirus Disease 2019 Treated With Hydroxychloroquine and/or Azithromycin.|pdf=|usr=}}
{{tp|p=34010161|t=2021. Tocilizumab-Associated Cecal Perforation in COVID-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33346946|t=2021. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33998136|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm.|pdf=|usr=}}
{{tp|p=34019051|t=2021. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.|pdf=|usr=}}
{{tp|p=33369927|t=2021. Is Aspirin Effective in Preventing Intensive Care Unit Admission in Patients With Coronavirus Disease 2019 Pneumonia?|pdf=|usr=}}
{{tp|p=34018416|t=2021. A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=34004274|t=2021. Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada.|pdf=|usr=}}
{{tp|p=33939483|t=2021. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).|pdf=|usr=}}
{{tp|p=34058104|t=2021. In COVID-19, tocilizumab reduces all-cause mortality at 28 d.|pdf=|usr=}}
{{tp|p=34058103|t=2021. In patients hospitalized with COVID-19, adding azithromycin to usual care did not reduce 28-d mortality.|pdf=|usr=}}
{{tp|p=34049853|t=2021. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.|pdf=|usr=}}
{{tp|p=34031032|t=2021. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.|pdf=|usr=}}
{{tp|p=34031031|t=2021. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.|pdf=|usr=}}
{{tp|p=33958323|t=2021. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.|pdf=|usr=}}
{{tp|p=33985941|t=2021. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al.|pdf=|usr=}}
{{tp|p=33903096|t=2021. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.|pdf=|usr=}}
{{tp|p=33903095|t=2021. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al.|pdf=|usr=}}
{{tp|p=33883160|t=2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.|pdf=|usr=}}
{{tp|p=34001511|t=2021. Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33972256|t=2021. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.|pdf=|usr=}}
{{tp|p=34033288|t=2021. Reasons to avoid vitamin D deficiency during COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=34011777|t=2021. [MANAGEMENT, DIAGNOSIS, AND TREATMENT OF SEVERE ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS TO COVID-19 VACCINE].|pdf=|usr=}}
{{tp|p=33881925|t=2021. Letter by Carmona et al Regarding Article, "Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: a National Population-Based Cohort Study".|pdf=|usr=}}
{{tp|p=33377184|t=2021. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.|pdf=|usr=}}
{{tp|p=33340765|t=2021. In vitro display evolution of IL-6R-binding unnatural peptides ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid.|pdf=|usr=}}
{{tp|p=34077310|t=2021. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network parmacology and molecular docking.|pdf=|usr=}}
{{tp|p=33858291|t=2021. Can algae contribute to the war with Covid-19?|pdf=|usr=}}
{{tp|p=33962976|t=2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.|pdf=|usr=}}
{{tp|p=33958384|t=2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.|pdf=|usr=}}
{{tp|p=33952506|t=2021. Thromboembolism and the Oxford-AstraZeneca vaccine.|pdf=|usr=}}
{{tp|p=33952443|t=2021. Covid-19: Two doses of Pfizer vaccine are "highly effective" against infection, hospital admission, and death, study finds.|pdf=|usr=}}
{{tp|p=33952439|t=2021. Covid-19: Vaccines will be tested against variants of concern after pound29m funding boost from UK government.|pdf=|usr=}}
{{tp|p=34049897|t=2021. Suspend intellectual property rights for covid-19 vaccines.|pdf=|usr=}}
{{tp|p=34045236|t=2021. Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds.|pdf=|usr=}}
{{tp|p=34039569|t=2021. Covid-19: Variants are spreading in countries with low vaccination rates.|pdf=|usr=}}
{{tp|p=34035010|t=2021. Covid-19: Are high rates of B.1.617.2 linked to vaccine hesitancy?|pdf=|usr=}}
{{tp|p=34006591|t=2021. Covid-19 vaccines: In the rush for regulatory approval, do we need more data?|pdf=|usr=}}
{{tp|p=34006531|t=2021. Covid-19: Most UK adults had antibodies after one dose of AstraZeneca or Pfizer vaccine, data suggest.|pdf=|usr=}}
{{tp|p=34001499|t=2021. Antivirals against SARS-CoV-2 by autumn?|pdf=|usr=}}
{{tp|p=33980548|t=2021. Covid-19: Fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show.|pdf=|usr=}}
{{tp|p=34074627|t=2021. On the road to Recovery-the world's biggest covid-19 treatment trial.|pdf=|usr=}}

{{tp|p=33978844|t=2021. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.|pdf=|usr=}}
{{tp|p=34029488|t=2021. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.|pdf=|usr=}}
{{tp|p=34029487|t=2021. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.|pdf=|usr=}}
{{tp|p=34029484|t=2021. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series.|pdf=|usr=}}
{{tp|p=33844575|t=2021. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.|pdf=|usr=}}
{{tp|p=34094533|t=2021. Convalescent plasma as a treatment modality for Coronavirus Disease 2019 in Indonesia: A case reports.|pdf=|usr=}}
{{tp|p=33932508|t=2021. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.|pdf=|usr=}}
{{tp|p=33932501|t=2021. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.|pdf=|usr=}}
{{tp|p=33894725|t=2021. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.|pdf=|usr=}}
{{tp|p=33849115|t=2021. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.|pdf=|usr=}}
{{tp|p=33894736|t=2021. A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment.|pdf=|usr=}}
{{tp|p=33832291|t=2021. Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.|pdf=|usr=}}
{{tp|p=33958324|t=2021. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.|pdf=|usr=}}
{{tp|p=33987222|t=2021. Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis.|pdf=|usr=}}
{{tp|p=34066998|t=2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.|pdf=|usr=}}
{{tp|p=33918619|t=2021. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.|pdf=|usr=}}
{{tp|p=33920366|t=2021. Sinapic Acid Suppresses SARS CoV-2 Replication by Targeting Its Envelope Protein.|pdf=|usr=}}
{{tp|p=34069726|t=2021. Effects of Antioxidant Vitamins, Curry Consumption, and Heavy Metal Levels on Metabolic Syndrome with Comorbidities: A Korean Community-Based Cross-Sectional Study.|pdf=|usr=}}
{{tp|p=34069549|t=2021. The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically Ill Patients: A Randomized Controlled Trial.|pdf=|usr=}}
{{tp|p=33922049|t=2021. Can Prophylactic High Flow of Humidified and Warmed Filtered Air Improve Survival from Bacterial Pneumonia and SARS-CoV-2 in Elderly Individuals? The Role of Surfactant Protein A.|pdf=|usr=}}
{{tp|p=33894278|t=2021. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33872675|t=2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro).|pdf=|usr=}}
{{tp|p=34010661|t=2021. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.|pdf=|usr=}}
{{tp|p=33309540|t=2021. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.|pdf=|usr=}}
{{tp|p=33826068|t=2021. RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33959781|t=2021. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.|pdf=|usr=}}
{{tp|p=33950278|t=2021. Potential role of IFN-alpha in COVID-19 patients and its underlying treatment options.|pdf=|usr=}}
{{tp|p=33876282|t=2021. Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.|pdf=|usr=}}
{{tp|p=33883784|t=2021. Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33358224|t=2021. Posibilidad de sesgo en estudio retrospectivo de ivermectina para COVID-19.|pdf=|usr=}}
{{tp|p=33994631|t=2021. Smoker, Former Smoker and COVID-19: Nicotine Does Not Protect Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33836322|t=2021. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: A systematic review.|pdf=|usr=}}
{{tp|p=32972773|t=2021. Status of Remdesivir: Not Yet Beyond Question!|pdf=|usr=}}
{{tp|p=32948379|t=2021. Response to: Status of Remdesivir: Not Yet Beyond Question!|pdf=|usr=}}
{{tp|p=34025857|t=2021. Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=34025855|t=2021. Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?|pdf=|usr=}}
{{tp|p=34025827|t=2021. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33747262|t=2021. Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?|pdf=|usr=}}
{{tp|p=33950349|t=2021. Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study.|pdf=|usr=}}
{{tp|p=34047940|t=2021. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.|pdf=|usr=}}
{{tp|p=33893998|t=2021. Phytochemistry and pharmacological activity of the genus artemisia.|pdf=|usr=}}
{{tp|p=34059544|t=2021. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33990984|t=2021. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33982806|t=2021. Interferon-alpha-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019.|pdf=|usr=}}
{{tp|p=33855727|t=2021. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.|pdf=|usr=}}
{{tp|p=33847002|t=2021. SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?|pdf=|usr=}}
{{tp|p=33982284|t=2021. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.|pdf=|usr=}}
{{tp|p=33904168|t=2021. Chilblain lesions after COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=33904157|t=2021. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33893637|t=2021. Pernio after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34097311|t=2021. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT).|pdf=|usr=}}
{{tp|p=34085278|t=2021. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.|pdf=|usr=}}
{{tp|p=34075578|t=2021. Exacerbation of immune thrombocytopenia following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34036570|t=2021. AZD1222 vaccine-related coagulopathy and thrombocytopenia without thrombosis in a young female.|pdf=|usr=}}
{{tp|p=33934330|t=2021. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=34044900|t=2021. Plant stanol esters might optimise the immune response and improve the SARS-CoV-2/COVID-19 vaccine efficacy in overweight and obese subjects.|pdf=|usr=}}
{{tp|p=33977890|t=2021. Vitamin D status of children with Paediatric Inflammatory Multisystem Syndrome Temporally associated with Severe acute respiratory syndrome coronavirus 2 (PIMS-TS).|pdf=|usr=}}
{{tp|p=34096487|t=2021. Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity.|pdf=|usr=}}
{{tp|p=34061355|t=2021. Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19.|pdf=|usr=}}
{{tp|p=33825201|t=2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.|pdf=|usr=}}
{{tp|p=34058750|t=2021. Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV.|pdf=|usr=}}
{{tp|p=34036326|t=2021. A multi-modal data harmonisation approach for discovery of COVID-19 drug targets.|pdf=|usr=}}
{{tp|p=33993214|t=2021. Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.|pdf=|usr=}}
{{tp|p=34081143|t=2021. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34089044|t=2021. Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design.|pdf=|usr=}}
{{tp|p=33831281|t=2021. Annual influenza vaccination effect on the susceptibility to COVID-19 infection.|pdf=|usr=}}
{{tp|p=33949124|t=2021. Atomistic De-novo Inhibitor Generation-Guided Drug Repurposing for SARS-CoV-2 Spike Protein with Free-Energy Validation by Well-Tempered Metadynamics.|pdf=|usr=}}
{{tp|p=33894099|t=2021. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.|pdf=|usr=}}
{{tp|p=34008627|t=2021. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model.|pdf=|usr=}}
{{tp|p=34002456|t=2021. Metal Complexes as Antiviral Agents for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33348462|t=2021. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=34092298|t=2021. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.|pdf=|usr=}}
{{tp|p=33825239|t=2021. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33969530|t=2021. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.|pdf=|usr=}}
{{tp|p=34081806|t=2021. COVID-19 vaccine-induced Stevens-Johnson syndrome.|pdf=|usr=}}
{{tp|p=34080223|t=2021. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33835617|t=2021. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients.|pdf=|usr=}}
{{tp|p=33896010|t=2021. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.|pdf=|usr=}}
{{tp|p=34061349|t=2021. Human CD4(+) T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential.|pdf=|usr=}}
{{tp|p=33836994|t=2021. What do we know about China's covid-19 vaccines?|pdf=|usr=}}
{{tp|p=33827801|t=2021. Incarcerated people should be prioritised for covid-19 vaccination.|pdf=|usr=}}
{{tp|p=33931384|t=2021. Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.|pdf=|usr=}}
{{tp|p=33883164|t=2021. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA.|pdf=|usr=}}
{{tp|p=33863757|t=2021. Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds.|pdf=|usr=}}
{{tp|p=33858846|t=2021. Covid-19: Single dose of Pfizer or AstraZeneca vaccine produces strong antibody response in over 80s.|pdf=|usr=}}
{{tp|p=33853865|t=2021. Thrombosis after covid-19 vaccination.|pdf=|usr=}}
{{tp|p=33849903|t=2021. Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial.|pdf=|usr=}}
{{tp|p=33849900|t=2021. Covid-19: EU investigates four reports of blood clots after Janssen vaccine.|pdf=|usr=}}
{{tp|p=33849893|t=2021. Covid-19: Chinese vaccines may need changes to improve efficacy, admits official.|pdf=|usr=}}
{{tp|p=33846162|t=2021. Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers.|pdf=|usr=}}
{{tp|p=33846122|t=2021. Reporting of AstraZeneca studies may have caused vaccine reservations.|pdf=|usr=}}
{{tp|p=33846115|t=2021. Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds.|pdf=|usr=}}
{{tp|p=33888547|t=2021. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.|pdf=|usr=}}
{{tp|p=33871897|t=2021. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.|pdf=|usr=}}
{{tp|p=33993472|t=2021. Ivermectin in the management of a scabies outbreak in a long-term care facility.|pdf=|usr=}}
{{tp|p=34045261|t=2021. Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management.|pdf=|usr=}}
{{tp|p=33355153|t=2021. Vitamin D and COVID-19 in older age: evidence versus expectations.|pdf=|usr=}}
{{tp|p=33314018|t=2021. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.|pdf=|usr=}}
{{tp|p=33336562|t=2021. Determinants of physical activity among adults in the United Kingdom during the COVID-19 pandemic: The DUK-COVID study.|pdf=|usr=}}
{{tp|p=33372846|t=2021. Considerations for COVID-19 Vaccination in Lactation.|pdf=|usr=}}
{{tp|p=33372839|t=2021. President's Corner: Introduction to ABM's Statement on Considerations for COVID-19 Vaccination in Lactation.|pdf=|usr=}}
{{tp|p=33990347|t=2021. Blood Cancers Diminish Response to COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33318035|t=2021. How Cancer Vaccine Tech Shaped COVID Response.|pdf=|usr=}}
{{tp|p=33331360|t=2021. A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.|pdf=|usr=}}
{{tp|p=34009959|t=2021. Safety of mRNA-Based Vaccines for SARS CoV-2.|pdf=|usr=}}
{{tp|p=33325938|t=2021. Biocatalytic routes to anti-viral agents and their synthetic intermediates.|pdf=|usr=}}
{{tp|p=33350032|t=2021. Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19.|pdf=|usr=}}
{{tp|p=34061468|t=2021. Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses.|pdf=|usr=}}
{{tp|p=33970560|t=2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.|pdf=|usr=}}
{{tp|p=33875170|t=2021. Comprehensive profiling and characterization of the absorbed components and metabolites in mice serum and tissues following oral administration of Qing-Fei-Pai-Du decoction by UHPLC-Q-Exactive-Orbitrap HRMS.|pdf=|usr=}}
{{tp|p=33838087|t=2021. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.|pdf=|usr=}}
{{tp|p=33914926|t=2021. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.|pdf=|usr=}}

{{tp|p=33535790|t=2021. Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study.|pdf=|usr=}}
{{tp|p=34007828|t=2021. Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000.|pdf=|usr=}}
{{tp|p=33793439|t=2021. Topical Ocular Povidone-Iodine as an Adjunctive Preventative Practice in the Era of COVID-19.|pdf=|usr=}}
{{tp|p=33360711|t=2021. Finding Horcrux of psychiatric symptoms in COVID-19: Deficiencies of amino acids and vitamin D.|pdf=|usr=}}
{{tp|p=34059849|t=2021. Immunising older Australians: Pre-COVID-19 vaccine perspectives from general practice training.|pdf=|usr=}}
{{tp|p=33911335|t=2021. ChAdOx1-S vaccine for prevention of COVID-19.|pdf=|usr=}}
{{tp|p=33911334|t=2021. BNT162b2 vaccine for prevention of COVID-19.|pdf=|usr=}}
{{tp|p=33326855|t=2021. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.|pdf=|usr=}}
{{tp|p=34026905|t=2021. Can trace element supplementations (Cu, Se, and Zn) enhance human immunity against COVID-19 and its new variants?|pdf=|usr=}}
{{tp|p=33773923|t=2021. Maternal vaccines-safety in pregnancy.|pdf=|usr=}}
{{tp|p=33965331|t=2021. Uptake of vaccination in pregnancy.|pdf=|usr=}}
{{tp|p=34056140|t=2021. Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface.|pdf=|usr=}}
{{tp|p=33364445|t=2021. Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing.|pdf=|usr=}}
{{tp|p=33309272|t=2021. Identification of antiviral antihistamines for COVID-19 repurposing.|pdf=|usr=}}
{{tp|p=33872570|t=2021. Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.|pdf=|usr=}}
{{tp|p=34082041|t=2021. Essential sufficiency of zinc, omega-3 polyunsaturated fatty acids, vitamin D and magnesium for prevention and treatment of COVID-19, diabetes, cardiovascular diseases, lung diseases and cancer.|pdf=|usr=}}
{{tp|p=33951913|t=2021. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.|pdf=|usr=}}
{{tp|p=33356169|t=2021. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33888980|t=2021. Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking.|pdf=|usr=}}
{{tp|p=34062724|t=2021. Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.|pdf=|usr=}}
{{tp|p=33910079|t=2021. PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses.|pdf=|usr=}}
{{tp|p=33360781|t=2021. 4-Aminoquinoline compounds from the Spanish flu to COVID-19.|pdf=|usr=}}
{{tp|p=33894625|t=2021. Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.|pdf=|usr=}}
{{tp|p=33866132|t=2021. Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33848774|t=2021. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?|pdf=|usr=}}
{{tp|p=33360048|t=2021. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?|pdf=|usr=}}
{{tp|p=34052565|t=2021. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.|pdf=|usr=}}
{{tp|p=34051617|t=2021. Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease.|pdf=|usr=}}
{{tp|p=34095308|t=2021. Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies.|pdf=|usr=}}
{{tp|p=34066608|t=2021. Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.|pdf=|usr=}}
{{tp|p=34063015|t=2021. Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-Based Study.|pdf=|usr=}}
{{tp|p=34067609|t=2021. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.|pdf=|usr=}}
{{tp|p=33918402|t=2021. Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs.|pdf=|usr=}}
{{tp|p=33919584|t=2021. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.|pdf=|usr=}}
{{tp|p=33372165|t=2021. COVID-19 Vaccine: Critical Questions with Complicated Answers.|pdf=|usr=}}
{{tp|p=34071582|t=2021. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.|pdf=|usr=}}
{{tp|p=34071060|t=2021. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.|pdf=|usr=}}
{{tp|p=34069869|t=2021. Povidone-Iodine Attenuates Viral Replication in Ocular Cells: Implications for Ocular Transmission of RNA Viruses.|pdf=|usr=}}
{{tp|p=33946644|t=2021. Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm.|pdf=|usr=}}
{{tp|p=33921886|t=2021. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.|pdf=|usr=}}
{{tp|p=33919870|t=2021. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33862474|t=2021. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.|pdf=|usr=}}
{{tp|p=33975232|t=2021. Synthesis, molecular docking, and in silico ADMET studies of 4-benzyl-1-(2,4,6-trimethyl-benzyl)-piperidine: Potential Inhibitor of SARS-CoV2.|pdf=|usr=}}
{{tp|p=33915460|t=2021. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.|pdf=|usr=}}
{{tp|p=33831697|t=2021. Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.|pdf=|usr=}}
{{tp|p=33957246|t=2021. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.|pdf=|usr=}}
{{tp|p=33984473|t=2021. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.|pdf=|usr=}}
{{tp|p=33940136|t=2021. Exploring the potential of novel phenolic compounds as potential therapeutic candidates against SARS-CoV-2, using quantum chemistry, molecular docking and dynamic studies.|pdf=|usr=}}
{{tp|p=33887440|t=2021. Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.|pdf=|usr=}}
{{tp|p=34089978|t=2021. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues.|pdf=|usr=}}
{{tp|p=33962341|t=2021. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.|pdf=|usr=}}
{{tp|p=33935291|t=2021. Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.|pdf=|usr=}}
{{tp|p=33342929|t=2021. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China.|pdf=|usr=}}
{{tp|p=33994673|t=2021. SARS-CoV-PL(pro)-Inhibitoren als mogliche Breitspektrum-Virostatika.|pdf=|usr=}}
{{tp|p=33666158|t=2021. Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=34050731|t=2021. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers.|pdf=|usr=}}
{{tp|p=34036334|t=2021. It is time to determine Tocilizumab place in COVID-19.|pdf=|usr=}}
{{tp|p=34015087|t=2021. Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.|pdf=|usr=}}
{{tp|p=33999992|t=2021. Cost-effectiveness of tocilizumab in severe COVID-19: to see or not to see.|pdf=|usr=}}
{{tp|p=33999127|t=2021. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.|pdf=|usr=}}
{{tp|p=33993265|t=2021. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.|pdf=|usr=}}
{{tp|p=33993228|t=2021. BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity.|pdf=|usr=}}
{{tp|p=33989390|t=2021. Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration.|pdf=|usr=}}
{{tp|p=34091665|t=2021. Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada.|pdf=|usr=}}
{{tp|p=34091664|t=2021. Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19.|pdf=|usr=}}
{{tp|p=34086881|t=2021. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees.|pdf=|usr=}}
{{tp|p=33735520|t=2021. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.|pdf=|usr=}}
{{tp|p=34057814|t=2021. Potential benefit of vitamin d supplementation in people with respiratory illnesses, during the Covid-19 pandemic.|pdf=|usr=}}
{{tp|p=33982445|t=2021. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34041932|t=2021. COVID-19 vaccine trials: The potential for "hybrid" analyses.|pdf=|usr=}}
{{tp|p=34029238|t=2021. Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine.|pdf=|usr=}}
{{tp|p=34091550|t=2021. Vaccine allergy: evidence to consider for COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34090785|t=2021. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?|pdf=|usr=}}
{{tp|p=33940227|t=2021. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.|pdf=|usr=}}
{{tp|p=32761148|t=2021. Hydroxychloroquine Failure: The End Does Not Justify the Means.|pdf=|usr=}}
{{tp|p=34079995|t=2021. The potential declining efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222) on inoculators with NSAIDs intake.|pdf=|usr=}}
{{tp|p=34045299|t=2021. mRNA COVID-19 Vaccine for People with Kidney Failure.|pdf=|usr=}}
{{tp|p=34031182|t=2021. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19.|pdf=|usr=}}
{{tp|p=33824157|t=2021. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.|pdf=|usr=}}
{{tp|p=33883486|t=2021. False-Positive Axillary Lymph Nodes on FDG PET/CT Resulting From COVID-19 Immunization.|pdf=|usr=}}
{{tp|p=34024569|t=2021. Can an anti-inflammatory diet be effective in preventing or treating viral respiratory diseases? A systematic narrative review.|pdf=|usr=}}
{{tp|p=33340409|t=2021. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.|pdf=|usr=}}
{{tp|p=34029377|t=2021. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.|pdf=|usr=}}
{{tp|p=34013969|t=2021. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=}}
{{tp|p=34077341|t=2021. Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34077664|t=2021. Vaccines for COVID-19: An Overview.|pdf=|usr=}}
{{tp|p=33951604|t=2021. Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2's protein via the application of amino acid grouping.|pdf=|usr=}}
{{tp|p=34049307|t=2021. Using Nonheparin Anticoagulant to Treat a Near-Fatal Case With Multiple Venous Thrombotic Lesions During ChAdOx1 nCoV-19 Vaccination-Related Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=}}
{{tp|p=34034298|t=2021. Increased Glucocorticoid Receptor Alpha Expression and Signaling in Critically Ill Coronavirus Disease 2019 Patients.|pdf=|usr=}}
{{tp|p=34049310|t=2021. Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=}}
{{tp|p=33870924|t=2021. Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment.|pdf=|usr=}}
{{tp|p=33870923|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.|pdf=|usr=}}
{{tp|p=34024199|t=2021. Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices.|pdf=|usr=}}
{{tp|p=33949929|t=2021. Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy.|pdf=|usr=}}
{{tp|p=34042026|t=2021. Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy.|pdf=|usr=}}
{{tp|p=34042025|t=2021. COVID-19: The significance of platelets, mitochondria, vitamin D, serotonin and the gut microbiota.|pdf=|usr=}}
{{tp|p=33992054|t=2021. Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses.|pdf=|usr=}}
{{tp|p=33881969|t=2021. SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions.|pdf=|usr=}}
{{tp|p=33982651|t=2021. To vaccinate or not to vaccinate; that is the question! (New insights on COVID-19 Vaccination).|pdf=|usr=}}
{{tp|p=34077352|t=2021. Evaluation of Dual Inhibitory Effect of Anagliptin, Ramipril, and Lisinopril on Angiotensin-Converting Enzyme and DPP-4 Activities.|pdf=|usr=}}
{{tp|p=33829974|t=2021. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19-induced Damage to the Nervous System.|pdf=|usr=}}
{{tp|p=34074880|t=2021. Coronavirus disease 2019 vaccination in transplant recipients.|pdf=|usr=}}
{{tp|p=33990506|t=2021. Coronavirus disease 2019, vitamin D and kidney function.|pdf=|usr=}}
{{tp|p=34097590|t=2021. Identification of novel drug candidates for the inhibition of catalytic cleavage activity of coronavirus 3CL-like protease enzyme.|pdf=|usr=}}
{{tp|p=33882805|t=2021. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.|pdf=|usr=}}
{{tp|p=33845735|t=2021. Olive oil consumption can prevent non-communicable diseases and COVID-19 : Review.|pdf=|usr=}}
{{tp|p=34009111|t=2021. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II).|pdf=|usr=}}
{{tp|p=33308117|t=2021. Chloroquine Analogs: An Overview of Natural and Synthetic Quinolines as Broad Spectrum Antiviral Agents.|pdf=|usr=}}
{{tp|p=33302855|t=2021. Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence.|pdf=|usr=}}
{{tp|p=34028347|t=2021. Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance.|pdf=|usr=}}
{{tp|p=33970846|t=2021. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.|pdf=|usr=}}
{{tp|p=33851937|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review.|pdf=|usr=}}

{{tp|p=33314794|t=2021. Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.|pdf=|usr=}}
{{tp|p=34002690|t=2021. Revisiting vitamin D status and supplementation for in-patients with intellectual and developmental disability in the North of England, UK.|pdf=|usr=}}
{{tp|p=33988688|t=2021. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.|pdf=|usr=}}
{{tp|p=33861303|t=2021. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.|pdf=|usr=}}
{{tp|p=33945618|t=2021. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.|pdf=|usr=}}
{{tp|p=33945605|t=2021. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.|pdf=|usr=}}
{{tp|p=33861315|t=2021. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.|pdf=|usr=}}
{{tp|p=33857940|t=2021. Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia.|pdf=|usr=}}
{{tp|p=34059190|t=2021. Position paper on the use of COVID-19 convalescent plasma: an update.|pdf=|usr=}}
{{tp|p=33832440|t=2021. Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.|pdf=|usr=}}
{{tp|p=33962573|t=2021. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.|pdf=|usr=}}
{{tp|p=33947344|t=2021. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=34058989|t=2021. Effects of early corticosteroid use in patients with severe coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=34044777|t=2021. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=34011281|t=2021. Association between fatality rate of COVID-19 and selenium deficiency in China.|pdf=|usr=}}
{{tp|p=34006228|t=2021. Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection.|pdf=|usr=}}
{{tp|p=33863281|t=2021. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33838657|t=2021. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.|pdf=|usr=}}
{{tp|p=33952445|t=2021. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.|pdf=|usr=}}
{{tp|p=34035040|t=2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.|pdf=|usr=}}
{{tp|p=33985964|t=2021. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.|pdf=|usr=}}
{{tp|p=33980718|t=2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.|pdf=|usr=}}
{{tp|p=33975825|t=2021. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.|pdf=|usr=}}
{{tp|p=33903131|t=2021. Prophylaxis against covid-19: living systematic review and network meta-analysis.|pdf=|usr=}}
{{tp|p=33762295|t=2021. Lateral ST-elevation myocardial infarction after donation of COVID-19 convalescent plasma in a naive donor.|pdf=|usr=}}
{{tp|p=33888484|t=2021. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.|pdf=|usr=}}
{{tp|p=34049903|t=2021. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review.|pdf=|usr=}}
{{tp|p=33574155|t=2021. Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial.|pdf=|usr=}}
{{tp|p=33853806|t=2021. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.|pdf=|usr=}}
{{tp|p=33358041|t=2021. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3.|pdf=|usr=}}
{{tp|p=33769875|t=2021. COVID-19 vaccination: intramuscular injection technique.|pdf=|usr=}}
{{tp|p=33910885|t=2021. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine.|pdf=|usr=}}
{{tp|p=33947605|t=2021. COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic - a follow up audit.|pdf=|usr=}}
{{tp|p=34075664|t=2021. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34033207|t=2021. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.|pdf=|usr=}}
{{tp|p=34031953|t=2021. Local reactions to the second dose of the BNT162 COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33955644|t=2021. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=34038246|t=2021. Reckoning gamma-Glutamyl-S-allylcysteine as a potential main protease (m(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=33960002|t=2021. TWIRLS, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via ACE2.|pdf=|usr=}}
{{tp|p=33847382|t=2021. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.|pdf=|usr=}}
{{tp|p=34089595|t=2021. Do Anti-androgens Have Potential as Therapeutics for COVID-19?|pdf=|usr=}}
{{tp|p=33928745|t=2021. COVID-19: vaccination problems.|pdf=|usr=}}
{{tp|p=34001753|t=2021. Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.|pdf=|usr=}}
{{tp|p=33987882|t=2021. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome.|pdf=|usr=}}
{{tp|p=34092488|t=2021. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=34090750|t=2021. SARS-CoV-2 vaccine-induced cerebral venous thrombosis.|pdf=|usr=}}
{{tp|p=34058925|t=2021. How can we accelerate COVID-19 vaccine discovery?|pdf=|usr=}}
{{tp|p=34088250|t=2021. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.|pdf=|usr=}}
{{tp|p=34078215|t=2021. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.|pdf=|usr=}}
{{tp|p=34092166|t=2021. Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST).|pdf=|usr=}}
{{tp|p=34004056|t=2021. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs.|pdf=|usr=}}
{{tp|p=34058321|t=2021. Nrf2 activator PB125(R) as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19.|pdf=|usr=}}
{{tp|p=34027650|t=2021. Phytotherapy for treatment of cytokine storm in COVID-19.|pdf=|usr=}}
{{tp|p=33973280|t=2021. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.|pdf=|usr=}}
{{tp|p=33369768|t=2021. Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.|pdf=|usr=}}
{{tp|p=33829614|t=2021. Delirium triggered by COVID-19 vaccine in an elderly patient.|pdf=|usr=}}
{{tp|p=34085396|t=2021. Acute kidney injury secondary to chlorine dioxide use for COVID-19 prevention.|pdf=|usr=}}
{{tp|p=34033528|t=2021. COVID-19 vaccine platforms: Delivering on a promise?|pdf=|usr=}}
{{tp|p=33966665|t=2021. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers.|pdf=|usr=}}
{{tp|p=33928831|t=2021. Drug delivery of amoxicillin molecule as a suggested treatment for covid-19 implementing functionalized mesoporous SBA-15 with aminopropyl groups.|pdf=|usr=}}
{{tp|p=33818031|t=2021. Drugs intervention study in COVID-19 management.|pdf=|usr=}}
{{tp|p=33378773|t=2021. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33890267|t=2021. A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions.|pdf=|usr=}}
{{tp|p=33931565|t=2021. COVID-19 vaccination in pregnancy.|pdf=|usr=}}
{{tp|p=34061008|t=2021. Revisiting the antiviral efficacy of terpenoids: Plausible adjunct therapeutics for novel SARS-CoV-2?|pdf=|usr=}}
{{tp|p=34057409|t=2021. Physicians' opinions on the necessity of COVID-19 vaccination in patients with epilepsy.|pdf=|usr=}}
{{tp|p=32725108|t=2021. End-stage heart failure secondary to low-dose hydroxychloroquine treatment.|pdf=|usr=}}
{{tp|p=33878713|t=2021. Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation).|pdf=|usr=}}
{{tp|p=33963635|t=2021. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.|pdf=|usr=}}
{{tp|p=34031153|t=2021. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results.|pdf=|usr=}}
{{tp|p=33990390|t=2021. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.|pdf=|usr=}}
{{tp|p=34083222|t=2021. Benefit versus toxicity risk of digoxin in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33832918|t=2021. Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.|pdf=|usr=}}
{{tp|p=33930196|t=2021. JAK inhibitors: Ten years after.|pdf=|usr=}}
{{tp|p=33832827|t=2021. Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33966314|t=2021. SARS-CoV-2 vaccine-related neurological complications need large collaborative studies, not single case reports or small descriptive series.|pdf=|usr=}}
{{tp|p=33843287|t=2021. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.|pdf=|usr=}}
{{tp|p=33886388|t=2021. Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33957833|t=2021. Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade.|pdf=|usr=}}
{{tp|p=33307875|t=2021. Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?|pdf=|usr=}}
{{tp|p=33345645|t=2021. Can drug repurposing strategies be the solution to the COVID-19 crisis?|pdf=|usr=}}
{{tp|p=33874829|t=2021. The role of IL-6 and IL-6 blockade in COVID-19.|pdf=|usr=}}
{{tp|p=33331197|t=2021. The COVID-19 pandemic: a target for surfactant therapy?|pdf=|usr=}}
{{tp|p=33858268|t=2021. Effects of select dietary supplements on the prevention and treatment of viral respiratory tract infections: a systematic review of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33945381|t=2021. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.|pdf=|usr=}}
{{tp|p=33853488|t=2021. Progress in research on the S protein as the target of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33350389|t=2021. Supplementation en vitamine D et Covid-19 : consensus d'experts et recommandations.|pdf=|usr=}}
{{tp|p=33860513|t=2021. Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia.|pdf=|usr=}}
{{tp|p=34034356|t=2021. Analysis of Homeopathic Genus Epidemicus for COVID-19 Patients in Spain.|pdf=|usr=}}
{{tp|p=33348417|t=2021. COVID-19 Pneumonia: A Potential Role of Homeopathy.|pdf=|usr=}}
{{tp|p=33930904|t=2021. Homeopathic Remedies in COVID-19: Prognostic Factor Research.|pdf=|usr=}}
{{tp|p=33853178|t=2021. Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India.|pdf=|usr=}}
{{tp|p=33853177|t=2021. Antimonium Tartaricum as a Possible Homeopathic Prophylactic Remedy in the COVID-19 Epidemic.|pdf=|usr=}}
{{tp|p=34005841|t=2021. Association between vitamin D level and prognostic factors among patients infected with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33998533|t=2021. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.|pdf=|usr=}}
{{tp|p=33858231|t=2021. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.|pdf=|usr=}}
{{tp|p=34033732|t=2021. Reactive arthritis after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=34032555|t=2021. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33857399|t=2021. Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations.|pdf=|usr=}}
{{tp|p=34015240|t=2021. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.|pdf=|usr=}}
{{tp|p=33377817|t=2021. The association of previous influenza vaccination and coronavirus disease-2019.|pdf=|usr=}}
{{tp|p=34081583|t=2021. LUNAR :Drug Screening for Novel Coronavirus Based on Representation Learning Graph Convolutional Network.|pdf=|usr=}}
{{tp|p=33914685|t=2021. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.|pdf=|usr=}}
{{tp|p=33941025|t=2021. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases.|pdf=|usr=}}
{{tp|p=33830864|t=2021. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults.|pdf=|usr=}}
{{tp|p=33955564|t=2021. A century of BCG: Impact on tuberculosis control and beyond.|pdf=|usr=}}
{{tp|p=34057870|t=2021. Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.|pdf=|usr=}}
{{tp|p=34032546|t=2021. Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4.|pdf=|usr=}}
{{tp|p=33356684|t=2021. Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review.|pdf=|usr=}}
{{tp|p=34047261|t=2021. A short review on key role of plants and their extracts in boosting up immune response to combat COVID-19.|pdf=|usr=}}

{{tp|p=33313690|t=2021. COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.|pdf=|usr=}}
{{tp|p=33857630|t=2021. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases.|pdf=|usr=}}
{{tp|p=33842899|t=2021. Boosting nitric oxide in stress and respiratory infection: Potential relevance for asthma and COVID-19.|pdf=|usr=}}
{{tp|p=33355812|t=2021. COVID-19 and Methylene Blue.|pdf=|usr=}}
{{tp|p=33866350|t=2021. Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy.|pdf=|usr=}}
{{tp|p=33839760|t=2021. Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.|pdf=|usr=}}
{{tp|p=33839740|t=2021. SMMPPI: a machine learning-based approach for prediction of modulators of protein-protein interactions and its application for identification of novel inhibitors for RBD:hACE2 interactions in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34009266|t=2021. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity.|pdf=|usr=}}
{{tp|p=34009288|t=2021. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.|pdf=|usr=}}
{{tp|p=33416848|t=2021. SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets.|pdf=|usr=}}
{{tp|p=33875896|t=2021. COVID-19 vaccin et anaphylaxie.|pdf=|usr=}}
{{tp|p=33902920|t=2021. La vaccination anti-COVID-19 et patients atteints de cancer : etat de l'art et synthese des recommandations.|pdf=|usr=}}
{{tp|p=33902918|t=2021. Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et preconisations d'un inter-groupe oncologique francais (CGO, TNCD, UNICANCER).|pdf=|usr=}}
{{tp|p=34025112|t=2021. Serial computed tomography findings of Coronavirus disease 2019 (COVID-19) pneumonia treated with favipiravir and steroid therapy: report of 11 cases.|pdf=|usr=}}
{{tp|p=33947599|t=2021. Timing of COVID-19 vaccination in the major burns patient.|pdf=|usr=}}
{{tp|p=33903009|t=2021. Radiotherapie de faible dose pour la pneumopathie covid-19 : rationnel biologique et revue de la litterature.|pdf=|usr=}}
{{tp|p=34090218|t=2021. COVID-19 patients' sera induce epithelial mesenchymal transition in cancer cells.|pdf=|usr=}}
{{tp|p=33910715|t=2021. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations.|pdf=|usr=}}
{{tp|p=34015720|t=2021. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).|pdf=|usr=}}
{{tp|p=33927910|t=2021. Vitamin D Deficiency Rickets and COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33836156|t=2021. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.|pdf=|usr=}}
{{tp|p=34087172|t=2021. Tackling COVID-19 with neutralizing monoclonal antibodies.|pdf=|usr=}}
{{tp|p=34051873|t=2021. A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro.|pdf=|usr=}}
{{tp|p=33979649|t=2021. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34031383|t=2021. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.|pdf=|usr=}}
{{tp|p=33894127|t=2021. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.|pdf=|usr=}}
{{tp|p=33359760|t=2021. Effects of vitamin D on macrophages and myeloid-derived suppressor cells (MDSCs) hyperinflammatory response in the lungs of COVID-19 patients.|pdf=|usr=}}
{{tp|p=33958745|t=2021. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.|pdf=|usr=}}
{{tp|p=34059790|t=2021. Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.|pdf=|usr=}}
{{tp|p=33984267|t=2021. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.|pdf=|usr=}}
{{tp|p=33852916|t=2021. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.|pdf=|usr=}}
{{tp|p=34074163|t=2021. Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report.|pdf=|usr=}}
{{tp|p=33845643|t=2021. Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis.|pdf=|usr=}}
{{tp|p=34067054|t=2021. The Discovery of Naringenin as Endolysosomal Two-Pore Channel Inhibitor and Its Emerging Role in SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=34068958|t=2021. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?|pdf=|usr=}}
{{tp|p=33917481|t=2021. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.|pdf=|usr=}}
{{tp|p=33946869|t=2021. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.|pdf=|usr=}}
{{tp|p=33887223|t=2021. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.|pdf=|usr=}}
{{tp|p=33991505|t=2021. A novel nano therapeutic using convalescent plasma derived exosomal (CP(Exo)) for COVID-19: A combined hyperactive immune modulation and diagnostics.|pdf=|usr=}}
{{tp|p=33974898|t=2021. Elucidating of oxidative distress in COVID-19 and methods of its prevention.|pdf=|usr=}}
{{tp|p=34007086|t=2021. Antiviral nucleoside analogs.|pdf=|usr=}}
{{tp|p=34007082|t=2021. Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins.|pdf=|usr=}}
{{tp|p=33850334|t=2021. In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex.|pdf=|usr=}}
{{tp|p=33362291|t=2021. Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium.|pdf=|usr=}}
{{tp|p=34024911|t=2021. Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations.|pdf=|usr=}}
{{tp|p=33994552|t=2021. Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine.|pdf=|usr=}}
{{tp|p=33994655|t=2021. An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods.|pdf=|usr=}}
{{tp|p=34025012|t=2021. Discovery of (E)-N-(4-cyanobenzylidene)- 6-fluoro- 3-hydroxypyrazine-2 -carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug.|pdf=|usr=}}
{{tp|p=34010501|t=2021. Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics.|pdf=|usr=}}
{{tp|p=33965141|t=2021. Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33965138|t=2021. Standard Dose Ivermectin for COVID-19.|pdf=|usr=}}
{{tp|p=33965137|t=2021. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).|pdf=|usr=}}
{{tp|p=33965134|t=2021. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.|pdf=|usr=}}
{{tp|p=33965120|t=2021. One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19.|pdf=|usr=}}
{{tp|p=33316235|t=2021. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype.|pdf=|usr=}}
{{tp|p=34021998|t=2021. Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=34031814|t=2021. Chinese Medicine Rescues Acute Respiratory Dyspnea Syndrome Caused by COVID-19: A Case Report.|pdf=|usr=}}
{{tp|p=34018412|t=2021. Thrombotic Events in COVID-19: Inquires About the Deleterious Procoagulant Effect of Corticosteroid Therapy.|pdf=|usr=}}
{{tp|p=33999204|t=2021. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.|pdf=|usr=}}
{{tp|p=33878754|t=2021. Spices and COVID-19.|pdf=|usr=}}
{{tp|p=34047498|t=2021. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination.|pdf=|usr=}}
{{tp|p=34080261|t=2021. Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study.|pdf=|usr=}}
{{tp|p=33971067|t=2021. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.|pdf=|usr=}}
{{tp|p=34089534|t=2021. COVID-19 vaccines and nanomedicine.|pdf=|usr=}}
{{tp|p=33998677|t=2021. Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2.|pdf=|usr=}}
{{tp|p=33900629|t=2021. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=33855706|t=2021. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33928638|t=2021. Leukocytoclastic vasculitis flare following the COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=34037266|t=2021. The use of cow dung and urine to cure COVID-19 in India: A public health concern.|pdf=|usr=}}
{{tp|p=33973379|t=2021. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.|pdf=|usr=}}
{{tp|p=34075419|t=2021. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study.|pdf=|usr=}}
{{tp|p=34075418|t=2021. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34037760|t=2021. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.|pdf=|usr=}}
{{tp|p=33973313|t=2021. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies.|pdf=|usr=}}
{{tp|p=34001719|t=2021. Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.|pdf=|usr=}}
{{tp|p=33993519|t=2021. Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus.|pdf=|usr=}}
{{tp|p=34097036|t=2021. Calcifediol treatment and COVID-19-related outcomes.|pdf=|usr=}}
{{tp|p=33959987|t=2021. Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19.|pdf=|usr=}}
{{tp|p=33870531|t=2021. Baricitinib: From Rheumatoid Arthritis to COVID-19.|pdf=|usr=}}
{{tp|p=34008285|t=2021. Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.|pdf=|usr=}}
{{tp|p=33978291|t=2021. Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=34074197|t=2021. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?|pdf=|usr=}}
{{tp|p=33817822|t=2021. Immunomodulatory and anti-inflammatory potential of crocin in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33913803|t=2021. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.|pdf=|usr=}}
{{tp|p=33891534|t=2021. Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33830908|t=2021. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=34054274|t=2021. Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?|pdf=|usr=}}
{{tp|p=33998306|t=2021. Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection.|pdf=|usr=}}
{{tp|p=33862126|t=2021. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluation.|pdf=|usr=}}
{{tp|p=33332179|t=2021. Reply to: regarding: 'the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case'.|pdf=|usr=}}
{{tp|p=33320755|t=2021. Low-dose radiotherapy (LD-RT) for COVID-19-induced pneumopathy: a worth considering approach.|pdf=|usr=}}
{{tp|p=33320738|t=2021. Regarding: "the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case".|pdf=|usr=}}
{{tp|p=33301368|t=2021. Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State.|pdf=|usr=}}
{{tp|p=33211596|t=2021. Intravenous sulforhodamine B reduces alveolar surface tension, improves oxygenation, and reduces ventilation injury in a respiratory distress model.|pdf=|usr=}}
{{tp|p=33934592|t=2021. SARS-CoV-2 infection versus the body immune defenses: the role of immune responses and mechanism of action of dexamethasone.|pdf=|usr=}}
{{tp|p=33904269|t=2021. Monoclonal antibody therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33896155|t=2021. Antibodies for COVID-19 - which, when and how long?|pdf=|usr=}}
{{tp|p=33982533|t=2021. Glycyrrhizin for topical use and prophylaxis of COVID-19: an interesting pharmacological perspective.|pdf=|usr=}}
{{tp|p=33947317|t=2021. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes.|pdf=|usr=}}
{{tp|p=33970805|t=2021. Medicinal plant compounds as promising inhibitors of coronavirus (COVID-19) main protease: an in silico study.|pdf=|usr=}}
{{tp|p=33685364|t=2021. An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor.|pdf=|usr=}}
{{tp|p=33826484|t=2021. Computational exploration of natural peptides targeting ACE2.|pdf=|usr=}}
{{tp|p=33928870|t=2021. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.|pdf=|usr=}}
{{tp|p=33908318|t=2021. Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors.|pdf=|usr=}}
{{tp|p=33372280|t=2021. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.|pdf=|usr=}}
{{tp|p=33368439|t=2021. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.|pdf=|usr=}}
{{tp|p=33350472|t=2021. Amantadine for COVID-19.|pdf=|usr=}}
{{tp|p=33843779|t=2021. Antibodies: Friends, Foes, or Both? Lessons From COVID-19 for the Rheumatologist.|pdf=|usr=}}
{{tp|p=33962499|t=2021. Herbal supplement (Combi-5) in the management of COVID 19 individual with mild to moderate symptoms: a case report.|pdf=|usr=}}
{{tp|p=33915020|t=2021. Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face.|pdf=|usr=}}
{{tp|p=33977807|t=2021. Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19.|pdf=|usr=}}
{{tp|p=33760271|t=2021. Study on the mechanism of active components of Liupao tea on 3CL(pro) based on HPLC-DAD fingerprint and molecular docking technique.|pdf=|usr=}}

{{tp|p=34084491|t=2021. Corticosteroid therapy for 2019-nCoV-infected patients: A case series of eight mechanically ventilated patients.|pdf=|usr=}}
{{tp|p=33936671|t=2021. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.|pdf=|usr=}}
{{tp|p=33972060|t=2021. Is the BCG vaccine a useful tool against COVID-19?|pdf=|usr=}}
{{tp|p=33997476|t=2021. The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors.|pdf=|usr=}}
{{tp|p=33969237|t=2021. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33845194|t=2021. The microbiota-mediated dietary and nutritional interventions for COVID-19.|pdf=|usr=}}
{{tp|p=33838340|t=2021. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.|pdf=|usr=}}
{{tp|p=33956936|t=2021. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality.|pdf=|usr=}}
{{tp|p=32588884|t=2021. Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33905481|t=2021. Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients.|pdf=|usr=}}
{{tp|p=33861337|t=2021. Impact of convalescent plasma therapy on SARS CoV-2 antibody profile in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33846730|t=2021. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study.|pdf=|usr=}}
{{tp|p=33953913|t=2021. Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis.|pdf=|usr=}}
{{tp|p=33479100|t=2021. Vitamin D.|pdf=|usr=}}
{{tp|p=33355217|t=2021. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.|pdf=|usr=}}
{{tp|p=34048876|t=2021. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=34044151|t=2021. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.|pdf=|usr=}}
{{tp|p=34020032|t=2021. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study.|pdf=|usr=}}
{{tp|p=33878505|t=2021. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.|pdf=|usr=}}
{{tp|p=33915284|t=2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.|pdf=|usr=}}
{{tp|p=33316402|t=2021. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.|pdf=|usr=}}
{{tp|p=34084692|t=2021. Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury.|pdf=|usr=}}
{{tp|p=33933296|t=2021. Polydatin and COVID-19.|pdf=|usr=}}
{{tp|p=33933295|t=2021. Nutritional risk at hospital admission is associated with prolonged length of hospital stay in old patients with COVID-19.|pdf=|usr=}}
{{tp|p=33933299|t=2021. Influence of foods and nutrients on COVID-19 recovery: A multivariate analysis of data from 170 countries using a generalized linear model.|pdf=|usr=}}
{{tp|p=33933297|t=2021. Early caloric deficit is associated with a higher risk of death in invasive ventilated COVID-19 patients.|pdf=|usr=}}
{{tp|p=33933298|t=2021. Region-specific COVID-19 risk scores and nutritional status of a high-risk population based on individual vulnerability assessment in the national survey data.|pdf=|usr=}}
{{tp|p=33353766|t=2021. Different barriers to nutritional therapy among critically-ill patients with COVID-19.|pdf=|usr=}}
{{tp|p=33349484|t=2021. The differential roles of zinc in immune responses and their potential implications in antiviral immunity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34049750|t=2021. Nutritional status in post SARS-Cov2 rehabilitation patients.|pdf=|usr=}}
{{tp|p=33934925|t=2021. Mediterranean diet and the risk of COVID-19 in the 'Seguimiento Universidad de Navarra' cohort.|pdf=|usr=}}
{{tp|p=34024561|t=2021. Safety and tolerance of enteral nutrition in COVID-19 critically ill patients, a retrospective study.|pdf=|usr=}}
{{tp|p=34024545|t=2021. Strengthening the immunity of the Swiss population with micronutrients: A narrative review and call for action.|pdf=|usr=}}
{{tp|p=34024544|t=2021. Energy expenditure and feeding practices and tolerance during the acute and late phase of critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=34024543|t=2021. The validity of the global leadership initiative on malnutrition criteria for diagnosing malnutrition in critically ill patients with COVID-19: A prospective cohort study.|pdf=|usr=}}
{{tp|p=34024542|t=2021. Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission.|pdf=|usr=}}
{{tp|p=34024527|t=2021. Serum vitamin D, calcium, and zinc levels in patients with COVID-19.|pdf=|usr=}}
{{tp|p=34024521|t=2021. Outcomes of nutritionally at-risk Coronavirus Disease 2019 (COVID 19) patients admitted in a tertiary government hospital: A follow-up study of the MalnutriCoV study.|pdf=|usr=}}
{{tp|p=34024518|t=2021. Influence of nutritional status on clinical outcomes among hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=34024514|t=2021. Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin.|pdf=|usr=}}
{{tp|p=34024511|t=2021. Prevalence and outcomes of malnutrition among hospitalized COVID-19 patients: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33864625|t=2021. Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".|pdf=|usr=}}
{{tp|p=33864624|t=2021. Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6".|pdf=|usr=}}
{{tp|p=33956042|t=2021. Patient safety recommendations and management in patients with COVID-19 pneumonia suspicion: a retrospective study.|pdf=|usr=}}
{{tp|p=34052007|t=2021. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.|pdf=|usr=}}
{{tp|p=34049725|t=2021. SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations.|pdf=|usr=}}
{{tp|p=34026115|t=2021. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.|pdf=|usr=}}
{{tp|p=34013493|t=2021. Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience.|pdf=|usr=}}
{{tp|p=34008772|t=2021. Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19.|pdf=|usr=}}
{{tp|p=33824151|t=2021. Le remdesivir chez les patients atteints de la COVID-19.|pdf=|usr=}}
{{tp|p=33866523|t=2021. Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.|pdf=|usr=}}
{{tp|p=33838582|t=2021. Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2.|pdf=|usr=}}
{{tp|p=34079039|t=2021. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells.|pdf=|usr=}}
{{tp|p=33893388|t=2021. Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33995820|t=2021. Therapeutic application of light and electromagnetic fields to reduce hyper-inflammation triggered by COVID-19.|pdf=|usr=}}
{{tp|p=33839522|t=2021. Traditional Chinese exercise potential role as prevention and adjuvant therapy in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33989861|t=2021. Adjunctive homeopathic treatment of hospitalized COVID-19 patients (COVIHOM): A retrospective case series.|pdf=|usr=}}
{{tp|p=34091029|t=2021. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33984653|t=2021. Designing potential siRNA molecule for the nucleocapsid(N) gene silencing of different SARS-CoV-2 strains of Bangladesh: Computational approach.|pdf=|usr=}}
{{tp|p=33845430|t=2021. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.|pdf=|usr=}}
{{tp|p=33360831|t=2021. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33352458|t=2021. Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.|pdf=|usr=}}
{{tp|p=33915361|t=2021. Promising phytochemicals of traditional Himalayan medicinal plants against putative replication and transmission targets of SARS-CoV-2 by computational investigation.|pdf=|usr=}}
{{tp|p=33895457|t=2021. Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.|pdf=|usr=}}
{{tp|p=33894500|t=2021. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.|pdf=|usr=}}
{{tp|p=33862305|t=2021. Virtual screening of peptides with high affinity for SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33845270|t=2021. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.|pdf=|usr=}}
{{tp|p=34090015|t=2021. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M(pro)): An integrated computational approach.|pdf=|usr=}}
{{tp|p=34020130|t=2021. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study.|pdf=|usr=}}
{{tp|p=34020129|t=2021. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.|pdf=|usr=}}
{{tp|p=34015671|t=2021. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.|pdf=|usr=}}
{{tp|p=33915479|t=2021. Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective.|pdf=|usr=}}
{{tp|p=33990955|t=2021. Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity.|pdf=|usr=}}
{{tp|p=33951210|t=2021. Maternal selenium status plays a crucial role on clinical outcomes of pregnant women with COVID-19 infection.|pdf=|usr=}}
{{tp|p=33942327|t=2021. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.|pdf=|usr=}}
{{tp|p=33913549|t=2021. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.|pdf=|usr=}}
{{tp|p=33851732|t=2021. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.|pdf=|usr=}}
{{tp|p=33788302|t=2021. Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19.|pdf=|usr=}}
{{tp|p=34076901|t=2021. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.|pdf=|usr=}}
{{tp|p=33856708|t=2021. Interferon beta-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease.|pdf=|usr=}}
{{tp|p=33792956|t=2021. Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study.|pdf=|usr=}}
{{tp|p=33788273|t=2021. Remdesivir for the treatment of COVID-19 in pregnancy.|pdf=|usr=}}
{{tp|p=33755218|t=2021. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33710631|t=2021. Assessment of the role of zinc in the prevention of COVID-19 infections and mortality: A retrospective study in the Asian and European population.|pdf=|usr=}}
{{tp|p=33675235|t=2021. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).|pdf=|usr=}}
{{tp|p=33982105|t=2021. The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.|pdf=|usr=}}
{{tp|p=33982128|t=2021. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes.|pdf=|usr=}}
{{tp|p=33938523|t=2021. Receptor-binding Domain Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibodies in Human Milk From Mothers With Coronavirus Disease 2019 Polymerase Chain Reaction or With Symptoms Suggestive of Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33980583|t=2021. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.|pdf=|usr=}}
{{tp|p=33860730|t=2021. From nicotine to the cholinergic anti-inflammatory reflex - Can nicotine alleviate the dysregulated inflammation in COVID-19?|pdf=|usr=}}
{{tp|p=34085075|t=2021. Nanoparticle-mediated surfactant therapy in patients with severe COVID-19: a perspective.|pdf=|usr=}}
{{tp|p=33539089|t=2021. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.|pdf=|usr=}}
{{tp|p=33775096|t=2021. Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH.|pdf=|usr=}}
{{tp|p=33891389|t=2021. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.|pdf=|usr=}}
{{tp|p=33835812|t=2021. Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV.|pdf=|usr=}}
{{tp|p=33689397|t=2021. Plant Metabolites as Antiviral Preparations Against Coronaviruses.|pdf=|usr=}}
{{tp|p=32926302|t=2021. Hydroxychloroquine Overdose: What Are the Exact Roles of Diazepam and Potassium Infusion?|pdf=|usr=}}
{{tp|p=34061377|t=2021. Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca(2+) -dependent membrane fusion.|pdf=|usr=}}
{{tp|p=33314173|t=2021. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence.|pdf=|usr=}}
{{tp|p=33336811|t=2021. Respiratory syndrome coronavirus-2 response: Microbiota as lactobacilli could make the difference.|pdf=|usr=}}
{{tp|p=33372690|t=2021. Rebuttal to overinterpretation of the antiviral results for human coronavirus 229E relative to severe acute respiratory syndrome coronavirus-2 by Rowpar Pharmaceuticals.|pdf=|usr=}}
{{tp|p=33368412|t=2021. Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare workers.|pdf=|usr=}}
{{tp|p=33325032|t=2021. The safety of remdesivir for COVID-19 patients.|pdf=|usr=}}
{{tp|p=33314219|t=2021. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.|pdf=|usr=}}
{{tp|p=33314166|t=2021. The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case-control study of hospitalized patients in Tehran, Iran.|pdf=|usr=}}
{{tp|p=33980349|t=2021. A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease.|pdf=|usr=}}
{{tp|p=33560122|t=2021. Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Hypocrella bambusae Are SARS-CoV-2 Entry Inhibitors.|pdf=|usr=}}
{{tp|p=33934125|t=2021. Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33906514|t=2021. The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19.|pdf=|usr=}}
{{tp|p=33882724|t=2021. Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series.|pdf=|usr=}}
{{tp|p=33853438|t=2021. Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report.|pdf=|usr=}}
{{tp|p=33302762|t=2021. A Response to the Recommendations for Using Dexamethasone for the Treatment of COVID-19: The Dark Side of Dexamethasone.|pdf=|usr=}}

{{tp|p=33903133|t=2021. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.|pdf=|usr=}}
{{tp|p=34055238|t=2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.|pdf=|usr=}}
{{tp|p=34002118|t=2021. Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition.|pdf=|usr=}}
{{tp|p=33936562|t=2021. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.|pdf=|usr=}}
{{tp|p=33841751|t=2021. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.|pdf=|usr=}}
{{tp|p=33312453|t=2021. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.|pdf=|usr=}}
{{tp|p=34074458|t=2021. The link between vitamin D and COVID-19.|pdf=|usr=}}
{{tp|p=34074457|t=2021. Response to the letter to the editor: "The link between Vitamin D and COVID-19".|pdf=|usr=}}
{{tp|p=34074339|t=2021. Hemofiltration with the Seraph((R)) 100 Microbind((R)) Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=34036275|t=2021. Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind.|pdf=|usr=}}
{{tp|p=33834168|t=2021. In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33986957|t=2021. The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome.|pdf=|usr=}}
{{tp|p=33981518|t=2021. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.|pdf=|usr=}}
{{tp|p=33936897|t=2021. Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial.|pdf=|usr=}}
{{tp|p=33564538|t=2021. Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=34035996|t=2021. Azithromycin in the Successful Management of COVID-19: A Family Physician's Perspective.|pdf=|usr=}}
{{tp|p=33890544|t=2021. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.|pdf=|usr=}}
{{tp|p=33877545|t=2021. A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33948913|t=2021. Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19.|pdf=|usr=}}
{{tp|p=33835432|t=2021. A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33323712|t=2021. Editorial: COVID-19 in older persons: the role of nutrition.|pdf=|usr=}}
{{tp|p=34052732|t=2021. Remdesivir for the treatment of Covid-19: the value of biochemical studies.|pdf=|usr=}}
{{tp|p=34029993|t=2021. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33907665|t=2021. Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?|pdf=|usr=}}
{{tp|p=33926774|t=2021. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.|pdf=|usr=}}
{{tp|p=33333393|t=2021. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.|pdf=|usr=}}
{{tp|p=33992887|t=2021. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.|pdf=|usr=}}
{{tp|p=34053857|t=2021. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?|pdf=|usr=}}
{{tp|p=33898670|t=2021. Design and manufacturability data on additively manufactured solutions for COVID-19.|pdf=|usr=}}
{{tp|p=33869690|t=2021. Data on the docking of phytoconstituents of betel plant and matcha green tea on SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33855133|t=2021. Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS.|pdf=|usr=}}
{{tp|p=33404148|t=2021. Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans.|pdf=|usr=}}
{{tp|p=33354849|t=2021. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses.|pdf=|usr=}}
{{tp|p=33838614|t=2021. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.|pdf=|usr=}}
{{tp|p=33319454|t=2021. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.|pdf=|usr=}}
{{tp|p=33310173|t=2021. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study.|pdf=|usr=}}
{{tp|p=33947009|t=2021. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.|pdf=|usr=}}
{{tp|p=34025036|t=2021. Theoretical investigation of favipiravir antiviral drug based on fullerene and boron nitride nanocages.|pdf=|usr=}}
{{tp|p=33919780|t=2021. Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases.|pdf=|usr=}}
{{tp|p=33867892|t=2021. Possible Potential Effects of Honey and Its Main Components Against Covid-19 Infection.|pdf=|usr=}}
{{tp|p=33976534|t=2021. Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.|pdf=|usr=}}
{{tp|p=34048893|t=2021. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.|pdf=|usr=}}
{{tp|p=33309533|t=2021. Potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=}}
{{tp|p=33892145|t=2021. Web resources facilitate drug discovery in treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33128226|t=2021. Tutankhamun's Antimalarial Drug for Covid-19.|pdf=|usr=}}
{{tp|p=33864232|t=2021. Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.|pdf=|usr=}}
{{tp|p=34047956|t=2021. Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".|pdf=|usr=}}
{{tp|p=33828607|t=2021. The effect of azoximer bromide (Polyoxidonium(R)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.|pdf=|usr=}}
{{tp|p=34097570|t=2021. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.|pdf=|usr=}}
{{tp|p=34074219|t=2021. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.|pdf=|usr=}}
{{tp|p=33993282|t=2021. The Challenging but Imperative Path to Monoclonal Antibody Use Against COVID-19 for a Small Overseas Military Hospital.|pdf=|usr=}}
{{tp|p=33993281|t=2021. Bamlanivimab Use in a Military Treatment Facility.|pdf=|usr=}}
{{tp|p=33904240|t=2021. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.|pdf=|usr=}}
{{tp|p=34018687|t=2021. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.|pdf=|usr=}}
{{tp|p=33963053|t=2021. Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome.|pdf=|usr=}}
{{tp|p=33910954|t=2021. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.|pdf=|usr=}}
{{tp|p=33963054|t=2021. ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33961002|t=2021. Precision Medicine for COVID-19: Phenotype Anarchy or Promise Realized?|pdf=|usr=}}
{{tp|p=33306087|t=2021. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.|pdf=|usr=}}
{{tp|p=34081086|t=2021. Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?|pdf=|usr=}}
{{tp|p=34081075|t=2021. Bamlanivimab for Prevention of COVID-19.|pdf=|usr=}}
{{tp|p=34081073|t=2021. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=34028504|t=2021. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33914069|t=2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33914066|t=2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19-Reply.|pdf=|usr=}}
{{tp|p=34087041|t=2021. Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole Schiff bases and molecular docking with ct-DNA and SARS-CoV-2 M(pro).|pdf=|usr=}}
{{tp|p=33958069|t=2021. In Reply - Safety of Convalescent Plasma Transfusion.|pdf=|usr=}}
{{tp|p=33958067|t=2021. Safety of Convalescent Plasma Transfusion.|pdf=|usr=}}
{{tp|p=33976099|t=2021. Fluvoxamine for COVID-19?|pdf=|usr=}}
{{tp|p=33830966|t=2021. An EUA for bamlanivimab and etesevimab for COVID-19.|pdf=|usr=}}
{{tp|p=33212200|t=2021. An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses.|pdf=|usr=}}
{{tp|p=33845740|t=2021. A therapeutic journey of potential drugs against COVID-19.|pdf=|usr=}}
{{tp|p=33355053|t=2021. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.|pdf=|usr=}}
{{tp|p=33280595|t=2021. Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33844232|t=2021. Antikorper-Duo verhindert schwere COVID-19-Verlaufe.|pdf=|usr=}}
{{tp|p=33328281|t=2021. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.|pdf=|usr=}}
{{tp|p=33945284|t=2021. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.|pdf=|usr=}}
{{tp|p=33356050|t=2021. Tocilizumab in Covid-19. Reply.|pdf=|usr=}}
{{tp|p=33356049|t=2021. Tocilizumab in Covid-19.|pdf=|usr=}}
{{tp|p=33378611|t=2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.|pdf=|usr=}}
{{tp|p=33378610|t=2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19.|pdf=|usr=}}
{{tp|p=33826817|t=2021. Preparing for the Future - Nanobodies for Covid-19?|pdf=|usr=}}
{{tp|p=33900318|t=2021. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M(pro) by large-scale molecular dynamic simulations combined with accurate binding free energy calculations.|pdf=|usr=}}
{{tp|p=33986543|t=2021. Tocilizumab for the treatment of severe COVID-19.|pdf=|usr=}}
{{tp|p=33837377|t=2021. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.|pdf=|usr=}}
{{tp|p=33949277|t=2021. Molecular docking of compounds from Clinacanthus nutans extract detected by GC-MS analysis with the SARS-CoV-2 main protease and ACE2 protein.|pdf=|usr=}}
{{tp|p=33949276|t=2021. Potential of (Citrus nobilis Lour x Citrus deliciosa Tenora) metabolites on COVID-19 virus main protease supported by in silico analysis.|pdf=|usr=}}
{{tp|p=33949266|t=2021. Can nutraceuticals assist treatment and improve covid-19 symptoms?|pdf=|usr=}}
{{tp|p=34027770|t=2021. Natural metabolites from the soft coral Nephthea sp. as potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=}}
{{tp|p=33864035|t=2021. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape.|pdf=|usr=}}
{{tp|p=33981021|t=2021. Structural basis for broad coronavirus neutralization.|pdf=|usr=}}
{{tp|p=33963326|t=2021. International COVID-19 trial to restart with focus on immune responses.|pdf=|usr=}}